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Background: No drug treatments are currently licensed for the treatment of borderline personality disorder
(BPD). Despite this, people with this condition are frequently prescribed psychotropic medications and often
with considerable polypharmacy. Preliminary studies have indicated that mood stabilisers may be of benefit
to people with BPD.
Objective: To examine the clinical effectiveness and cost-effectiveness of lamotrigine for people with BPD.
Design: A two-arm, double-blind, placebo-controlled individually randomised trial of lamotrigine versus
placebo. Participants were randomised via an independent and remote web-based service using permuted
blocks and stratified by study centre, the severity of personality disorder and the extent of hypomanic
symptoms.
Setting: Secondary care NHS mental health services in six centres in England.
Participants: Potential participants had to be aged ≥ 18 years, meet diagnostic criteria for BPD and provide
written informed consent. We excluded people with coexisting psychosis or bipolar affective disorder, those
already taking a mood stabiliser, those who spoke insufficient English to complete the baseline assessment
and women who were pregnant or contemplating becoming pregnant.
Interventions: Up to 200 mg of lamotrigine per day or an inert placebo. Women taking combined oral
contraceptives were prescribed up to 400 mg of trial medication per day.
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Main outcome measures: Outcomes were assessed at 12, 24 and 52 weeks after randomisation.
The primary outcome was the total score on the Zanarini Rating Scale for Borderline Personality Disorder
(ZAN-BPD) at 52 weeks. The secondary outcomes were depressive symptoms, deliberate self-harm, social
functioning, health-related quality of life, resource use and costs, side effects of treatment and adverse
events. Higher scores on all measures indicate poorer outcomes.
Results: Between July 2013 and October 2015 we randomised 276 participants, of whom 195 (70.6%)
were followed up 52 weeks later. At 52 weeks, 49 (36%) of those participants prescribed lamotrigine and
58 (42%) of those prescribed placebo were taking it. At 52 weeks, the mean total ZAN-BPD score was
11.3 [standard deviation (SD) 6.6] among those participants randomised to lamotrigine and 11.5 (SD 7.7)
among those participants randomised to placebo (adjusted mean difference 0.1, 95% CI –1.8 to 2.0;
p = 0.91). No statistically significant differences in secondary outcomes were seen at any time. Adjusted
costs of direct care for those prescribed lamotrigine were similar to those prescribed placebo.
Limitations: Levels of adherence in this pragmatic trial were low, but greater adherence was not
associated with better mental health.
Conclusions: The addition of lamotrigine to the usual care of people with BPD was not found to be
clinically effective or provide a cost-effective use of resources.
Future work: Future research into the treatment of BPD should focus on improving the evidence base for
the clinical effectiveness and cost-effectiveness of non-pharmacological treatments to help policy-makers
make better decisions about investing in specialist treatment services.
Trial registration: Current Controlled Trials ISRCTN90916365.
Funding: Funding for this trial was provided by the Health Technology Assessment programme of the
National Institute for Health Research (NIHR) and will be published in full in Health Technology Assessment;
Vol. 22, No. 17. See the NIHR Journals Library website for further project information. The Imperial
Biomedical Research Centre Facility, which is funded by NIHR, also provided support that has contributed to
the research results reported within this paper. Part of Richard Morriss’ salary during the project was paid by
NIHR Collaboration for Leadership in Applied Health Research and Care East Midlands.
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Plain English summary
People with borderline personality disorder (BPD) experience high levels of emotional distress and rapidand upsetting changes in mood. No medications are currently available for people with this condition.
‘Mood stabilisers’ are known to reduce mood swings in people with bipolar affective disorder and the
results of small-scale studies suggest that they may also help people with BPD.
We conducted a clinical trial of the mood stabiliser lamotrigine for people with BPD who were using
mental health services. We compared the effects of lamotrigine with those of a placebo (a dummy pill
that did not contain any active drug) so that neither the researchers nor the participants knew what
treatment they had been given until after we had completed an initial analysis of the results of the study.
We assessed mental health, social functioning, quality of life, side effects and use of services in the year
after people entered the study.
A total of 276 participants took part and 195 were followed up 1 year later. Fewer than half the
participants (39%) were taking trial medication regularly at 1 year. We found no difference in mental
health or any of the other outcomes we measured between those who were prescribed lamotrigine and
those prescribed the placebo. We checked to see if the results were affected by whether or not people
were taking their medication regularly and found no difference between those taking lamotrigine and
those taking the placebo. On the basis of the results of this study, we have not shown any benefits of
lamotrigine for treating people with BPD. Further research is needed to find out how best to help improve
the mental health of people with this condition.
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Scientific summary
Background
Borderline personality disorder (BPD) is a severe mental health condition that is associated with poor
mental health, rapid and distressing fluctuations in mood and an increased risk of suicidal behaviour.
No medication is currently licensed for the treatment of BPD. National guidance on the treatment of people
with BPD highlighted the potential value of mood stabilisers but concluded that there was insufficient
evidence to recommend the use of any drug in the treatment of this condition. Lamotrigine is a mood
stabiliser that reduces fluctuations in mood among people with bipolar affective disorder and prevents
episodes of depression in these patients. Compared with other mood stabilisers, lamotrigine is relatively
safe in overdose. Two small-scale clinical trials of lamotrigine for people with BPD found improvements in
emotional health among those randomised to lamotrigine compared with those randomised to placebo.
Neither trial examined the long-term effects of lamotrigine or examined the costs and cost-effectiveness
of this approach in trying to help people with BPD.
The Lamotrigine And Borderline personality disorder: Investigating Long-term Effectiveness (LABILE) trial
was designed to generate high-quality evidence on the clinical effectiveness and cost-effectiveness of
lamotrigine for people with BPD.
Objectives
The main objective of the study was to establish whether or not prescribing lamotrigine to people with
BPD provides a clinically effective and cost-effective use of resources. To achieve this objective, we:
1. tested whether or not adding lamotrigine to usual care improves mental health over a 12-month period
2. examined whether or not the addition of lamotrigine to usual care improves social functioning and
health-related quality of life, reduces the incidence of suicidal behaviour and lowers the amount of
psychotropic medication that people are prescribed
3. examined the cost and cost-effectiveness of adding lamotrigine to the treatment of people with BPD.
Methods
Study design
The study design was a two-arm, parallel-group, double-blind, placebo-controlled, randomised trial with
an integrated economic evaluation.
Setting
Study participants were recruited from inpatient units and outpatient clinics in six secondary care mental
health services in England: Central and North West London NHS Foundation Trust, Derbyshire Healthcare
NHS Foundation Trust, Nottinghamshire Healthcare NHS Foundation Trust, Oxleas NHS Foundation Trust,
Tees, Esk and Wear Valleys NHS Foundation Trust and West London Mental Health NHS Trust.
Target population
The target population was people aged ≥ 18 years who were in contact with mental health services and
met the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) diagnostic criteria for
BPD using the Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). We excluded
those who met the diagnostic criteria for bipolar affective disorder, those already taking lamotrigine and
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those unable to speak sufficient English to complete the baseline assessment. We also excluded any
potential participant who was breastfeeding or pregnant at the time of the baseline assessment, planning
or contemplating becoming pregnant during the following 12 months or pre-menopausal, sexually active
and unwilling to take regular contraception.
Health technologies assessed
All those taking part in the study continued to receive treatment as usual from primary and secondary care
services. In addition, those who were randomised to the active arm of the trial were prescribed capsules
containing up to 200 mg of generic lamotrigine titrated over a 6-week period, depending on how well it
was tolerated and clinical response. In keeping with clinical recommendations, this regime was modified
for women taking the combined oral contraceptive pill, who were prescribed up to 400 mg daily.
Those participants randomised to the control arm of the trial were prescribed an inert placebo in capsules
that were identical in appearance to the capsules containing lamotrigine but which were backfilled with
lactose monohydrate, using the same titration regime as those in the active arm of the trial.
Measurement of costs and outcomes
Our primary outcome was symptoms of BPD measured at 12 months using total score on the Zanarini
Rating Scale for Borderline Personality Disorder (ZAN-BPD). The ZAN-BPD is a widely used measure of the
symptoms and behavioural problems experienced by people with BPD.
Our secondary outcomes were measured at baseline and at 3, 6 and 12 months after randomisation:
mental health (using ZAN-BPD and the Beck Depression Inventory), deliberate self-harm (using the
Acts of Deliberate Self-Harm Inventory), social functioning (using the Social Functioning Questionnaire),
health-related quality of life [using the EuroQoL-5 Dimensions, three-level version (EQ-5D-3L)], side effects
of treatment, adverse reactions and medication adherence. Resource use and costs were assessed using a
modified version of the Adult Service Use Schedule. This questionnaire collects detailed data on use of all
hospital and community services, including medication. All assessments were conducted by researchers
who were masked to allocation status.
Study logistics
Staff working in mental health services were asked to identify potential participants. Those willing to meet
with a researcher were provided with verbal and written information about the study and asked whether
or not they would be willing to take part. Those participants who provided written informed consent
were assessed for eligibility using the SCID-II to establish if the participant met the criteria for BPD, and
the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) to establish whether or not they had
coexisting bipolar affective disorder. Those who were eligible were then assessed using study outcome
measures, an assessment of their personality (using the International Personality Disorder Examination),
hypomanic symptoms [using the Hypomanic Checklist-32 items (HCL-32)] and use of alcohol and other
drugs using the Alcohol, Smoking and Substance Involvement Screening Test. Study participants were then
randomised centrally by the Nottingham Clinical Trials Unit using a remote web-based system. We used
permuted stacked blocks stratified by study centre, severity of personality disorder and extent of
hypomanic symptoms. The block size was randomly assigned between 4 and 6.
Sample size
The sample size for the study was calculated on the basis of our primary hypothesis: that, for people with
BPD who are in contact with mental health services, the addition of lamotrigine to their usual treatment
would reduce the symptoms of their disorder at 52 weeks according to the total score on the ZAN-BPD.
We calculated that 214 participants (receiving lamotrigine, n = 107; receiving placebo, n = 107) would need
to be randomised to have 90% power to detect a minimal clinically relevant difference of 3.0 [standard
deviation (SD) 6.75] in total score on the ZAN-BPD at 12 months, using a 0.05 level of statistical significance.
To take account of 15% loss to follow-up at 6 months, we increased the sample size to 246 participants.
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Data analysis
The primary analysis was performed according to the intention-to-treat principle, without imputation of missing
data. The analysis was adjusted by site, baseline ZAN-BPD score, severity of personality disorder (simple or
complex) and score on the HCL-32 (score of ≥ 14 or < 14). For the secondary analysis of ZAN-BPD scores,
groups were compared using a mixed model for repeated outcome measures adjusted by the same
stratification variables used for the primary analysis. We investigated whether any treatment effects were
sustained or emerged later by including an interaction term between treatment with lamotrigine and time
in the model. In the absence of a time effect, the effectiveness parameter was the average difference in
mean ZAN-BPD score over the 52-week period, along with 95% confidence interval (CI) and exact p-value.
Further sensitivity analyses were conducted to adjust for any variable with marked imbalance at baseline
and investigate the impact of missing data, using multiple imputation.
We investigated the effect of treatment adherence using complier-average causal effect (CACE) estimation
methods according to whether or not the participant has taken medication at a dose of ≥ 100 mg without
interruption during the 52 weeks prior to the final follow-up interview. Analyses of secondary outcomes
used similar methods to those in the primary analysis. We used general linear models for continuous
outcomes and logistic regression models for binary outcomes.
For safety data, including adverse events (AEs), serious adverse events (SAEs) and suspected unexpected
serious adverse reactions, we used basic summary statistics, that is, the number of AEs/side effects of
different categories and the number and proportion of participants who reported at least one AE or SAE
within each treatment arm.
The primary cost-effectiveness analysis involved comparing incremental differences in total costs and
incremental differences in mental health assessed using the ZAN-BPD. In a secondary cost–utility
analysis, we compared incremental differences in costs with differences in quality of life measured using
quality-adjusted life-year (QALYs) derived from the EQ-5D-3L.
Results
Between July 2013 and October 2015, 296 patients were assessed for eligibility, of whom 276 (93.2%)
met eligibility criteria and were randomised: 137 to lamotrigine plus usual care and 139 to placebo
plus usual care. The mean age of the study sample was 36.1 years (SD 11.0 years) and three-quarters
were female. A total of 195 (70.7%) participants completed the 52-week follow-up. A total of 93 (34%)
participants reported taking trial medication as per protocol; the proportion was similar in both arms.
There was no difference in adjusted total ZAN-BPD score at 52 weeks between treatment arms (11.3 in
the active arm and 11.5 in the control arm of the trial; difference 0.1, 95% CI –1.8 to 2.0). The lack of
treatment effect was supported by the results of sensitivity analyses. Differences between groups were
not seen for secondary outcomes or at the 12- or 26-week follow-up assessment. The results of the CACE
analysis also showed no differences between treatment groups. Regarding AEs, 77 (56%) of those in the
lamotrigine arm of the trial experienced one or more events, compared with 93 (67%) of those in
the control arm of the trial. The corresponding figures for SAEs were 26 (19%) in the active arm of the
trial and 32 (23%) in the control arm.
At baseline, costs were, on average, £5618 in the lamotrigine group and £3555 in the placebo group. The
average total costs over 52 weeks were £12,244.32 in the lamotrigine group and £8495.41 in the control
arm of the trial. The difference in cost was not statistically significant (p = 0.617). Group differences
between health-related quality of life and the resulting QALYs were also not statistically significant.
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Implications for health care
We found no evidence of benefit from prescribing lamotrigine to people with BPD beyond those associated
with prescribing an inert placebo. We did not show any beneficial effects of lamotrigine for the treatment of
people with BPD. It is important to differentiate emotional instability seen in bipolar disorder with that seen
in BPD, as lamotrigine can be an effective treatment for people with bipolar disorder.
Recommendations for future research
1. Future research should examine ways that clinicians can help people with BPD manage at times of crisis
without recourse to pharmacotherapy.
2. Further research should test the clinical effectiveness and cost-effectiveness of structured psychological
treatments compared with structured clinical care for people with BPD
3. The role of atypical antipsychotic drugs in the treatment of impulsive and self-harming behaviour
among people with severe BPD warrants further investigation.
Trial registration
This trial is registered as ISRCTN90916365.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research. The Imperial Biomedical Research Centre Facility, which is funded by
the National Institute for Health Research, also provided support that has contributed to the research
results reported within this paper. Part of Richard Morriss’ salary during the project was paid by NIHR
Collaboration for Leadership in Applied Health Research and Care East Midlands.
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Chapter 1 Introduction
The importance of borderline personality disorder
Borderline personality disorder (BPD) is a severe mental health condition that is characterised by affective
instability, recurrent suicidal behaviour and impaired interpersonal functioning.1 It is estimated that between
0.5% and 2% of people have BPD.2 The levels of BPD among people in contact with mental health services
are far higher; as many as one-fifth of people who are admitted to inpatient mental health units in the UK
have this diagnosis.3
People with BPD are more likely to experience other mental health problems such as anxiety, depression
and substance misuse. Of those who attend emergency medical services following deliberate self-harm,
1 in 10 have BPD,4 and the rate of completed suicide among people with this condition is 50 times higher
than in the general population.5 People with this condition have poor social functioning; many are socially
isolated and most are unemployed or on long-term sick leave.6 People with BPD are also more likely to
experience poor physical health7 and mortality due to cardiovascular disease and other physical health
problems is higher.8 The reasons for this are unclear. Although it is possible that the high levels of emotional
distress that people with BPD experience are associated with more somatic symptoms,9 it seems likely that
higher levels of smoking and substance misuse are important.10 People with BPD may neglect themselves,
and problems in maintaining interpersonal relationships may make it more difficult for them to obtain the
physical health care they need when unwell.10
Treatment of borderline personality disorder
Concerns have been expressed about the quality of services for people with BPD.11 Many people who
have this diagnosis report that they are dissatisfied with the treatment they receive,12,13 and mental health
practitioners often find it difficult to work with people with this condition.14
Although psychological treatments, such as dialectical behaviour therapy and mentalisation-based therapy,
have been shown to improve the mental health of people with BPD,15 most people with this disorder do
not have access to specialist psychological treatment services. Among those who do, many do not engage
with psychological treatment, and as many as half of those who do engage drop out before the treatment
has been completed.16 People with the most severe problems are less likely to engage successfully in
psychological treatments than those with milder forms of the disorder.16,17
No drug treatments are licensed for the treatment of BPD. Despite this, people with this condition are often
prescribed large amounts of psychotropic medication.18 Antidepressants are widely used, despite evidence
that they do not improve the mental health or social functioning of people with BPD.19 The results of
randomised trials of antipsychotic medications are equivocal. Although some studies have shown short-term
reductions in symptoms of anger and hostility, the longer-term effects of these drugs are not known.19
The role of mood stabilisers
Affective instability and higher than expected levels of comorbidity with bipolar disorder among people
with BPD have led to considerable interest in the role that mood stabilisers may play in improving the
mental health of people with this disorder.20 Investigation of the role of mood stabilisers was highlighted
as a priority for future research in the National Institute for Health and Care Excellence (NICE) guidelines
on the recognition and management of BPD.11 Research into the effects of established mood stabilisers,
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such as lithium and carbamazepine, has been limited because of their toxicity in overdose, which is a
not infrequent occurrence among people with this condition.21 Another concern about the use of mood
stabilisers in people with BPD is the increased incidence of birth defects among children born to women
taking these drugs.22 Most people with BPD who are in contact with mental health services are women
of child-bearing age. Many women with BPD report impulsive behaviour, including unplanned and
unprotected sex. Data from women who take these drugs for epilepsy have shown that levels of major
congenital malformations are higher among those taking valproate than among those taking lamotrigine.23
Concerns have also been raised about long-term cognitive impairment among children born to women
taking valproate.24
Lamotrigine is a mood stabiliser with antiepileptic and analgesic properties.25,26 The mechanism of action
of lamotrigine in patients with bipolar affective disorder is poorly understood but may relate to enhancing
the action of the inhibitory neurotransmitters, including gamma-aminobutyric acid.27
Evidence in support of the use of lamotrigine for people with BPD comes from three open-label studies
and two placebo-controlled trials.19 The two randomised controlled trials of lamotrigine for people with
BPD have reported positive findings. The first trial, by Tritt et al.,28 involved 24 women who were recruited
mainly from advertisements placed in primary care practices. In comparison with those women taking the
placebo, women taking up to 200 mg of lamotrigine were found to have lower levels of anger 8 weeks
later. The second trial, by Reich et al.,29 recruited 28 men and women through websites and television and
radio advertisements. Those participants who were randomised to receive up to 225 mg of lamotrigine
were subsequently found to have lower levels of affective instability and impulsiveness [assessed using the
Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD)] 12 weeks later. A key limitation of
both studies is that the degree of severity may have been lower than that seen among people with BPD
who are treated in secondary care mental health services. Data on levels of global functioning at the time
of the baseline assessment in the trial by Reich et al.29 show that mean levels of impaired social function
were in the ‘moderate’ range. Both studies focused on short-term effects of lamotrigine and neither
examined the costs or cost-effectiveness of this intervention.
Lamotrigine is associated with a range of side effects, which include a skin rash that is reported in up to
10% of people taking the drug and a more severe cutaneous reaction, Stevens–Johnson syndrome, which
is estimated to occur in < 0.1% of people taking this drug.30 The incidence of this problem is reduced
by gradual dose escalation and care with interacting agents, such as valproate and oral contraceptives.
However, serious events are rare, and the drug is widely used in the UK for the treatment of people with
bipolar disorder; therefore, psychiatrists are familiar with its dose titration requirements and the need for
vigilance regarding severe cutaneous adverse reactions.
The LABILE study
The Lamotrigine And Borderline personality disorder: Investigating Long-term Effectiveness (LABILE) trial
was designed to compare the clinical effectiveness and cost-effectiveness of lamotrigine plus usual care
with an inactive placebo plus usual care over a 1-year period. The main aim of the study was to test
whether or not prescribing lamotrigine in addition to usual treatment reduces symptoms of this condition,
improves social functioning and quality of life, reduces the incidence of suicidal behaviour, reduces the
level of alcohol and substance misuse and lowers the amount of antipsychotic and other psychotropic
medication that people are prescribed. The trial also examined the cost, cost-effectiveness and cost–utility
of adding lamotrigine to usual care for adults with BPD.
INTRODUCTION
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Chapter 2 Methods
Design
The LABILE trial was a multicentre, two-arm, parallel-group, double-blind, placebo-controlled, individually
randomised trial of lamotrigine versus placebo with 12-, 24- and 52-week follow-up assessments. The trial
included an integrated clinical and economic evaluation.
Study setting
Study participants were recruited from secondary care mental health services in England including inpatient
units, outpatient clinics and community mental health teams. There were six recruitment centres altogether
in London (Central and North West London NHS Foundation Trust, Oxleas NHS Foundation Trust, West
London Mental Health NHS Trust), the East Midlands (Nottinghamshire Healthcare NHS Foundation Trust,
Derbyshire Healthcare NHS Foundation Trust) and the north-east of England (Tees, Esk and Wear Valleys
NHS Foundation Trust).
Participants
To be eligible to take part in the study, potential participants had to be aged ≥ 18 years, meet the
Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) diagnostic criteria for
BPD and be willing and able to provide written informed consent to take part in the study. Potential
participants were excluded if they:
1. had a coexisting diagnosis of bipolar affective disorder (type I and II) or psychotic disorder
(schizophrenia, schizoaffective disorder or mood disorder with psychotic features)
2. were already being prescribed a mood stabiliser (lithium, carbamazepine or valproate) or had had one
within the past 4 weeks
3. had a known medical history of liver or kidney impairment
4. had cognitive or language difficulties that prevented them from providing informed consent.
In addition to this, women were excluded from the study if they were pregnant, planning a pregnancy or
of child-bearing age and not using adequate contraception.
Interventions
Those who were allocated to the active arm of the trial were prescribed encapsulated generic lamotrigine,
titrated according to the established British National Formulary protocol30 but with the titration occurring at
standardised 14-day intervals. The dose was altered for participants who were taking the combined oral
contraceptive pill, which affects the metabolism of lamotrigine. For all participants, the starting dose was
25 mg per day and this was increased to 50 mg after 2 weeks, 100 mg after 4 weeks and 200 mg per day
after 6 weeks. The dose was maintained at 200 mg unless the participant was taking the combined oral
contraceptive pill, in which case it was further increased to 300 mg after 8 weeks and 400 mg per day
after 10 weeks. However, the same dose could be prescribed again for an additional 2 weeks during
titration and a lower maintenance dose utilised throughout participation when this was clinically indicated,
such as when tolerability or emergent side effects were a concern.
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Those who were allocated to the placebo arm of the trial were given capsules identical in appearance to
those containing active lamotrigine, but backfilled with lactose monohydrate. This was prescribed in the
same regime as that used in the active arm of the trial.
Trial medication was issued to patients fortnightly to cover the dose titration period, with a 17-day supply
provided in case the next supply was delayed for any reason, such as a participant not attending a scheduled
meeting. Once the maintenance dose was reached, further trial medication was provided either fortnightly
or 4-weekly, as decided by the prescriber based on an assessment of risk of intentional overdose. In any
instance when a participant had, intentionally or unintentionally, stopped taking trial medication for a period
of ≥ 5 consecutive days, they were returned to a prescribed dosage of 25 mg daily and re-titrated gradually
to their maintenance dose.
Usual care
Usual care in the trial comprised contact with primary care and secondary care health services, including
access to psychological treatment services and inpatient admission if required. No restrictions were imposed
on the use of other treatments, except that those who remained in the trial were not to be prescribed
lamotrigine (aside from trial medication) or any other mood stabiliser (lithium, carbamazepine or sodium
valproate).
Assessments
Assessment of eligibility and for determining randomisation strata
We assessed eligibility using the items on BPD from the Structured Clinical Interview for DSM-IV Axis II
Personality Disorders (SCID-II).31,32 We planned to use data from other sections of the SCID-II to establish
the severity of the participant’s personality disorder33 but, following feedback from researchers and
service users, we replaced this with the self-completed International Personality Disorder Examination
(IPDE) screening questionnaire (DSM-IV version) to reduce the amount of time that it took to complete
the baseline assessment.34 We used the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)35
to assess whether or not potential participants had bipolar affective disorder (type I or II) and excluded
those who did. Hypomanic symptoms were assessed using the Hypomanic Checklist-32 items (HCL-32),36
a relatively short screening questionnaire that can distinguish those with bipolar disorder from those with
unipolar depression.
Primary outcome
The primary outcome was symptoms of BPD measured using the ZAN-BPD37 52 weeks after randomisation.
The ZAN-BPD is a widely used measure of the symptoms and behavioural problems experienced by people
with BPD. The scale includes four subscores for the domains of affective disturbance, cognitive disturbance,
impulsivity and disturbed relationships, which characterise the signs and symptoms of BPD. The ZAN-BPD has
been used in previous studies of pharmacological and psychological treatments for people with BPD.29,38–40
It is reliable (intraclass correlation coefficients for inter-rater reliability = 0.96 and test–retest reliability = 0.93),
has high convergent validity with structured clinical ratings of symptoms of BPD and is sensitive to change.37
The lead researcher on the study received personal training on the use of the ZAN-BPD from Professor
Mary Zanarini (who developed the scale). This researcher then trained the other researchers, initially by
using vignettes and then by discussing participants whom they had assessed. In order to test the reliability
of the assessment of the primary outcome among researchers, we arranged for 27 participants to be
simultaneously rated by two separate researchers and we calculated the extent to which total scores on
the scale were correlated.
METHODS
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Secondary outcomes
The following secondary outcomes were assessed:
1. Scores on the ZAN-BPD in the 52 weeks after randomisation using repeated measures analysis of data
collected at 12, 24 and 52 weeks’ follow-up.
2. Total score on the 21-item Beck Depression Inventory (BDI)41 at 12, 24 and 52 weeks. The BDI has been
widely used as a self-completed questionnaire, provides a valid assessment of the severity of depressive
symptoms and can be completed in less than 10 minutes.42
3. Incidence and severity of suicidal behaviour and self-harm using the Acts of Deliberate Self-Harm
Inventory43 at 12, 24 and 52 weeks. This structured interview collects detailed information about the
number and severity of episodes of self-harm and suicidal acts, and has been used successfully in other
trials of treatments for people with BPD.44
4. Social functioning using the Social Functioning Questionnaire (SFQ) at 12, 24 and 52 weeks. This
questionnaire is an eight-item self-report scale that asks people about problems across a range of
settings that people with BPD often experience.45
5. Health-related quality of life, using the EuroQoL-5 Dimensions, three-level version (EQ-5D-3L),46 at
12, 24 and 52 weeks. The EQ-5D-3L provides a brief and reliable measure of health-related quality
of life, which is responsive to change in people with BPD.47
6. Side effects, using a pro forma designed to cover the possible effects listed in the British National
Formulary entry for lamotrigine,30 at 12, 24, and 52 weeks (see Appendix 1).
7. Use of alcohol and other drugs at 52 weeks after randomisation, using the Alcohol, Smoking and
Substance Involvement Screening Test (ASSIST).48 This short questionnaire provides a reliable and valid
screening test for problem substance use.49
8. Use of concomitant psychotropic medication, defined as the proportion of people taking psychotropic
medication and the proportion of people taking antipsychotics, at 52 weeks after randomisation.
9. Total cost of health and social services. We collected data on use of resource using the Adult Service
Use Schedule (AD-SUS), adapted for use in this trial based on previous research involving people with
personality disorders,50 at 12, 24 and 52 weeks (see Appendix 2). This questionnaire collects detailed
data on use of all hospital and community health and social care services. At baseline, we used the
AD-SUS to record service use over the previous 12 weeks and at the trial follow-up time points we used
the AD-SUS to record service use since the previous assessment; thus, the entire study period was covered.
Adherence
We assessed adherence to study medication at the 12-, 24- and 52-week assessments using the Morisky
Medication four-item Adherence Scale.51 This is a four-item questionnaire that provides a valid estimate of
adherence with psychotropic medication.52 The total score ranges from 0 to 4, with higher scores indicating
higher adherence. In addition to this, researchers asked participants about their use of trial medication when
each prescription was renewed and any intentional or unintentional treatment breaks were recorded.
Blinding
All patients, carers and referring psychiatrists were blinded to treatment assignment until the participant
had left the trial or until 52 weeks post randomisation (whichever was the longer). Blinding of investigators,
researchers, the trial manager and the trial statistician was maintained until all data were entered, the
database was locked and initial analyses of trial data were complete. The exception to this was for
participants whose referring psychiatrist was also the principal investigator, in which case the allocation for
that particular participant was revealed following the final assessment.
Site pharmacies were unblinded to trial arm allocation and were provided with a list of the randomisation
codes and corresponding trial arm allocation for that site. The trial medication was produced with tear-off
labels that identified it as being lamotrigine or placebo in a coded format, so that pharmacy staff could
dispense the appropriate medication for a participant. Pharmacy procedures required that the tear-off label
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was removed during dispensing and added to trial documents for accountability. The need to maintain the
blinding of researchers and other individuals at the site was made clear to those delegated to work on the
trial within the pharmacy.
Unblinding at the end of the follow-up period
At 52 weeks after a participant was randomised into the study, regardless of whether or not they withdrew
from the study early or completed the participation period in full, a letter was sent to the referring prescriber
informing them of the participant’s allocation status. When a participant had completed the participation
period in full, this allowed the prescriber time to make arrangements for the participant to continue on
lamotrigine if appropriate and desired. On completion of the 52-week follow-up assessment, the participant
was advised to contact their prescriber to discuss their trial arm allocation and their future treatment.
An individual, who had no other role in the trial, was unblinded for the purpose of informing the referring
clinician of the trial arm of the allocation of participants, as part of routine unblinding.
Emergency unblinding
In anticipation of an emergency, such as an overdose of trial medication, Emergency Scientific and Medical
Services (ESMS) Global Ltd was contracted to provide a 24-hour emergency unblinding telephone service.
All requests for unblinding were recorded.
Study logistics
Recruitment
Potential participants were initially approached about the trial by any health-care professional who was
involved in their care, providing that the consultant psychiatrist for the team had agreed in principle to
patients under their care taking part in the study.
If a psychiatrist or other health-care professional had a patient under their care who they believed met the
eligibility criteria, they then introduced the patient to the trial and provided them with an information sheet.
When the patient provided verbal agreement to discuss their eligibility and possible enrolment into the trial
with a member of the research team, a screening number was assigned and contact details passed on to
the research team to discuss consent.
Potential participants were given a minimum of 24 hours from receiving the information sheet to consider
the information and the opportunity to question the investigator, their general practitioner (GP) or other
independent parties regarding participation in the trial.
Screening and baseline
If written informed consent was given and documented, then the referring clinician completed a document
to confirm their medical opinion of the participant’s eligibility and a researcher completed the screening
assessment (Table 1) with the participant to assess eligibility. If the participant fulfilled all the eligibility
criteria, then the baseline assessment was also completed and they were randomised into the trial.
Following randomisation, the participant’s GP and consultant were informed of their enrolment into the trial.
Assignment of interventions
Study participants were randomly allocated to the intervention (lamotrigine) or comparator (placebo)
arm of the trial by an automated randomisation service operated by Nottingham Clinical Trials Unit. The
randomisation sequence was generated using permuted stacked blocks, with block size randomly assigned
to 4 or 6. Allocation was 1 : 1, stratified by recruitment site, severity of personality disorder and extent
of bipolarity. We used data from the IPDE screening questionnaire to establish whether participants met
criteria for probable cluster A or cluster C personality disorders (‘complex personality disorder’) or whether
METHODS
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they met only probable criteria for borderline and other cluster B personality disorders (‘simple personality
disorder’) according to the criteria developed by Tyrer and Johnson.33 We used the extent of bipolarity,
measured as total score on the HCL-32, to examine the extent of bipolarity (low, a score of 0–13, or high,
a score of ≥ 14).54
Follow-up
Prior to providing a new supply of trial medication, the participant was contacted to elicit details of any
adverse events (AEs) that occurred, to determine if there had been any intentional or unintentional breaks
in their taking of the trial mediation and to ascertain whether or not they wished to continue with the trial.
Participants received an assessment at 12, 24 and 52 weeks. The timing and sequence of all assessments
are summarised in Table 1.
Data management
Data were entered onto a secure web-based database. Access was restricted by user identifiers and
passwords (encrypted using a one-way encryption method). Study data will be archived securely and then
safely destroyed after 15 years.
Sample size
We based the sample size calculation for the study on our primary hypothesis: for people with BPD who
are in contact with mental health services, the addition of lamotrigine to usual treatment will reduce
symptoms of their disorder at 52 weeks’ follow-up, according to the total score on the ZAN-BPD.
TABLE 1 Study assessment schedule53
Assessments
Time point
Screening Baseline
Follow-up
12-week 24-week 52-week
SCID-IIa ✗ – – – –
SCID-Ib ✗ – – – –
IPDE screening questionnaire (DSM-IV version) ✗ – – – –
HCL-32 ✗ – – – –
ASSIST – ✗ – – ✗
Four-item Morisky Medication Adherence Scale – – ✗ ✗ ✗
ZAN-BPD – ✗ ✗ ✗ ✗
BDI – ✗ ✗ ✗ ✗
Acts of Deliberate Self-harm Inventory – ✗ ✗ ✗ ✗
SFQ – ✗ ✗ ✗ ✗
EQ-5D-3L – ✗ ✗ ✗ ✗
Side effects – ✗ ✗ ✗ ✗
Modified Adult Service User Schedule – ✗ ✗ ✗ ✗
a Section on BPD.
b Section on bipolar affective disorder (types I and II).
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The ZAN-BPD has been used to examine the clinical effectiveness of a range of psychological and
pharmacological treatments for people with BPD. In a randomised trial of a modified form of group-based
cognitive behavioural therapy, Blum et al.40 found that there were improvements in mental health and reduced
use of emergency medical services among those who were randomised to problem-solving therapy. These
improvements were associated with a difference of 3.6 [standard deviation (SD) 6.9] in total ZAN-BPD score.
The ZAN-BPD rating scale was also used to examine the clinical effectiveness of lamotrigine for people with
BPD in a randomised trial conducted by Reich et al.29 In this small trial (n = 28), a non-statistically significant
difference of 5.6 (SD 6.75) in total score on the ZAN-BPD was found at 12 weeks. Seventeen (61%) people
in the trial completed all 12 weeks of the study and the levels of adherence to trial medications in those that
completed the study were judged to be high.
Anticipating that levels of adherence to trial medications would be lower in the LABILE trial than in the
study by Reich et al.,29 we powered the study on the basis of a smaller difference in ZAN-BPD score of 3.0
(SD 6.75). The sample size was calculated using Stata® version 13.1 (StataCorp LP, College Station, TX, USA).
A total of 214 participants (107 receiving lamotrigine and 107 receiving placebo) would need to be
randomised to have 90% power to detect a minimal clinically relevant difference of 3.0 (SD 6.75) in total
score on the ZAN-BPD at 52 weeks, using a 0.05 level of statistical significance. To take account of 15%
loss to follow-up at 52 weeks, the sample size was increased to 252. However, this was further revised to
266 during the course of the trial to account for a greater loss to follow-up of 25%.
Statistical analyses
The analysis and reporting of the trial was conducted in accordance with Consolidated Standards of
Reporting Trials (CONSORT) guidelines.55 A detailed statistical analysis plan was developed and agreed with
the Independent Data Monitoring and Ethics Committee, and this was finalised prior to the completion of
data collection, the database lock and the unblinding of the study. Continuous variables were summarised in
terms of the mean, SD, median, lower and upper quartiles, minimum, maximum and number of observations.
Categorical variables were summarised in terms of frequency counts and percentages. All data were analysed
using Stata, version 13.1.
Preliminary analyses
Descriptive statistics of demographic and clinical measures were used to examine the balance between the
randomised arms at baseline.
Primary analysis
The primary analysis was performed according to the intention-to-treat principle on the available case set,
without imputation of missing data. The analysis was adjusted by site, baseline ZAN-BPD score, severity of
personality disorder (simple or complex) and the extent of bipolarity (score of ≥ 14 or < 14).
Secondary analyses
For secondary analyses of ZAN-BPD scores at 12 and 24 weeks, randomised groups were compared using
a mixed model for repeated outcome measures, adjusted by the same stratification variables used for the
primary analysis. We investigated whether any treatment effects were sustained or emerged later by
including an interaction term between treatment and time in the model. In the absence of a time effect,
the effectiveness parameter was the average difference in mean ZAN-BPD score over the 52-week period
along with 95% confidence interval (CI) and exact p-value.
METHODS
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Sensitivity analyses
Sensitivity analyses of the primary outcome were conducted to:
1. further adjust for any variable with marked imbalance at baseline
2. investigate the impact of missing data, using multiple imputation.
Complier-average causal effect analyses
We investigated the effect of treatment adherence using complier-average causal effect (CACE) estimation
methods. Intention-to-treat analysis does not represent treatment effect under non-compliance of treatment;
therefore, we used CACE analysis to explore whether or not the treatment effect was directly affected by
the level of compliance. The level of compliance was examined using both dichotomous and continuous
measures: (1) dichotomous – whether or not the participant had taken medication at a dose of ≥ 100 mg
without interruption during the 52 weeks prior to the final follow-up interview; and (2) continuous – the
percentage of weeks that the patient took the medication at a dose of ≥ 100 mg during the 52-week
treatment period.
Analyses of secondary outcomes
The secondary outcomes were BDI score, incidence of deliberate self-harm, SFQ score, alcohol and any
other substance use, and antipsychotic medication use. The secondary outcomes were analysed in a similar
manner to the primary analysis. A generalised linear model was used for continuous outcomes and logistic
regression model for binary outcomes.
Safety reporting
For safety data, including AEs, serious adverse events (SAEs) and suspected unexpected serious adverse
reactions, we presented basic summary statistics, that is, the number of AEs or side effects of different
categories and the number and proportion of participants who reported at least one AE or SAE within
each treatment arm.
Health economics analysis
The primary economic evaluation took a NHS/personal social services perspective, including only costs
incurred to health and social care services, following guidance from NICE.56 Although previous studies
in people with BPD have found that health and social care are the key cost drivers in this patient group,44
it is also clear that BPD can have an impact on not only an individual’s ability to work but also their
absence from work as a result of sickness.57 Therefore, productivity losses were included in a sensitivity
analysis.
Calculation of costs
Costs for the economic evaluation were calculated in three stages: identification, measurement and
valuation. The first stage of identification ensures that all relevant resources are included in the evaluation;
these are the resources that are particularly relevant for people with BPD and which were identified from
published studies,44,58 meetings with clinicians and discussions with our patient representatives. Resource
use was collected in the following areas:
l lamotrigine – drug costs and time with dispensing clinician
l hospital services – inpatient admissions (including admissions for physical and mental health problems),
outpatient/day case appointments (for physical and mental health problems), accident and emergency
attendances
l community services – GP (in person, on the telephone and at home), practice nurse, mental health
care co-ordinator/key worker, psychiatrist, psychologist, community psychiatric nurse, social worker,
counsellor/therapist, NHS walk-in clinic, advice service (e.g. Citizens Advice), complementary therapist
l medication.
DOI: 10.3310/hta22170 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 17
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Crawford et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9
During data collection there was also an opportunity for respondents to report any other relevant service
use, including group therapy, day centre, dietitian, drug and alcohol services, eating disorder services,
physiotherapist or podiatrist.
Data on the use of all identified services were collected using a range of methods. Information on the
dispensing and dosage of lamotrigine was taken from clinician records. Other data were obtained from
participants using a modified version of the AD-SUS, adapted for use in people with BPD on the basis of
previous research in this area.58 The use of community services was collected in interview, in which the
study participant was asked to recall which, from a list of community services, they had contacted over
the previous period. In addition, researchers used the AD-SUS to collect information on the participant’s
occupational status (e.g. employed, unemployed, student, retired) and the number of hours and days
taken off work as a result of ill-health. The AD-SUS was administered at baseline and at 12, 24 and
52 weeks’ follow-up. At baseline, the participant was asked to recall the services that they had used over
the previous 12 weeks and at the trial follow-up time points, the participant was asked, using the AD-SUS,
about the services that they had used since the previous assessment, so that the entire follow-up period
was covered.
The total cost of the resources used by each study participant was calculated by applying a unit cost to
each item of resource use. All unit costs were for the financial year 2015/16. The cost of lamotrigine was
taken from the British National Formulary,59 using a generic cost from a standard NHS supplier. The cost
of time with the dispensing clinician was taken from the Unit Costs of Health and Social Care.60 It was
assumed that the clinician was a psychiatrist, who had a 10-minute consultation with the participant
during the titration period, followed by 10 minutes every 4 weeks thereafter. All other unit costs were
sourced from standard sources and are detailed in Appendix 3. Productivity losses were calculated on the
basis of days missed from work using information on gross annual pay collected in the AD-SUS. The total
cost for each participant was the sum of all their costs. Discounting was not necessary, as costs were
collected over a 1-year period only.
Calculation of quality-adjusted life-years
The EQ-5D-3L responses were converted to utility scores using findings from a sample of representative
UK adults.61 These utility scores were then used to calculate quality-adjusted life-years (QALYs) using the
area under the curve approach, in which changes in utility scores were assumed to follow a linear path.62
No discounting of QALYs was necessary.62
Data analysis
For the main analysis, complete-case analysis was used in which participants with missing data were
excluded. Multiple imputation of missing cases was carried out in a sensitivity analysis. A single missing
item from an otherwise complete data set was imputed using mean imputation, so that the participant
could be included in the complete-case analysis.
The average use of different types of services by randomised group over 52 weeks’ follow-up was tabulated
and reported descriptively as the mean number of contacts and the percentage of each group using that
service at least once. No statistical comparisons between service uses were completed in order to avoid
problems with multiple testing and to keep the focus of the evaluation on costs and cost-effectiveness.
The total average cost between randomised groups over 52 weeks’ follow-up was compared using
generalised linear regression models with the following covariates: stratification variables (study centre,
severity of personality disorder and extent of bipolarity) and baseline costs. The validity of the results were
confirmed by examining the CIs from bias-corrected, non-parametric bootstrapping.63 The use of parametric
tests is recommended for cost data, despite its skewed distribution, because it allows for inferences to be
made on the arithmetic mean, which is the most meaningful summary statistic for cost.64
METHODS
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Cost-effectiveness analysis
The cost-effectiveness analysis allowed costs and outcomes to be considered together in a decision-making
context. The primary cost-effectiveness analysis used QALYs derived from the EQ-5D-3L; a secondary
cost-effectiveness analysis used the ZAN-BPD measure. Cost-effectiveness was first assessed through the
calculation of incremental cost-effectiveness ratios (ICERs), which are a summary statistic of the difference
in mean cost between randomised groups divided by the difference in mean effect.65 An ICER is calculated
from the means of the randomised group, so there remains statistical uncertainty as to the accuracy of the
ICER as a summary statistic. Therefore, 5000 resamples (bootstrapping) from the cost and outcomes data
were used to generate a new distribution of mean costs and outcomes.66 These distributions were then
plotted onto a cost-effectiveness plane for interpretation.65 Replications that fall in the south-west quadrant
of the plane suggest that lamotrigine is less costly and less effective than the placebo, replications that fall
in the south-east quadrant suggest that lamotrigine is less costly and more effective than the placebo,
replications in the north-west quadrant suggest that lamotrigine is more costly and less effective than the
placebo and replications in the north-east quadrant suggest that lamotrigine is more costly and more
effective than the placebo.
Next, the bootstrapped replications were used to calculate the probability that lamotrigine was the ‘optimal’
choice, depending on the maximum value (willingness to pay, λ) that a decision-maker might be willing to
pay for an improvement in outcome. The willingness-to-pay value varied between likely minimum and
maximum values, and the results plotted on a graph result in a cost-effectiveness acceptability curve.67 All
cost-effectiveness analyses were adjusted for baseline stratification variables by site, baseline ZAN-BPD score,
severity of personality disorder (simple or complex) and score on the HCL-32 (i.e. a score of ≥ 14 or < 14),
baseline costs and baseline EQ-5D-3L tariff.
Sensitivity analysis
A number of sensitivity analyses were carried out to test the robustness of the analysis to key assumptions:
1. varying the economic perspective to include productivity losses
2. examining the impact of missing data through multiple imputation of missing cases.
Service user involvement
Plans for the study were presented at a research seminar at the British and Irish Group for the Study of
Personality Disorder, which included service user representatives. These discussions, together with feedback
from Fenella Lemonsky (an expert by experience and a co-applicant on the study), helped us to decide
which mood stabiliser we should examine. We also used feedback from service users and results of a
Delphi study of users of personality disorder services to help us decide.58
Fenella Lemonsky remained an active member of the project management group throughout the study.
Additional input from people with lived experience of using services was provided by Sally Strange and
Jennie Parker. Service users reviewed materials for publicising the study and commented on a draft version
of the patient information sheet.
Service users also contributed to the communication of study findings; Sally Strange and Jennie Parker
helped us interpret study findings and develop our recommendations for services and for future research.
Jennie Parker also commented on a draft of the lay summary of the study findings, which we have
distributed to study participants, and Fenella Lemonsky presented the results of the study at the annual
conference of the British and Irish Group for the Study Personality Disorders in 2017.
An independent service user, Jenny Trite, was an active member of the Trial Steering Group throughout
the course of the study.
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Ethics approval and governance
The trial was approved by the London-Central Research Ethics Committee (reference number 2/LO/1514).
In accordance with the current revision of the Declaration of Helsinki68 (amended October 2000, with
additional footnotes added in 2002 and 2004), a participant had the right to stop trial treatment and
to withdraw from the trial at any time and for any reason, without prejudice to his or her future medical
care by the physician or at the institution, and was not obliged to give his or her reasons for doing so.
The investigator could also withdraw a participant from trial treatment at any time in the interest of the
participant’s health and well-being or for administrative reasons. Trial follow-up continued after treatment
was withdrawn, unless the participant withdrew consent.
All potential participants were provided with written and verbal information about the study before being
asked to provide written informed consent to participate in the study.
Progress of the study was overseen by a Trial Steering Committee and a Data Monitoring and
Ethics Committee.
Changes to trial design
Change to design between funding proposal and trial commencement
1. Following concerns about the length of time it would take to assess eligibility, we modified our initial
plan, which was to assess all aspects of personality disorder using the SCID-II semistructured interview
(which can take up to 90 minutes to complete), and instead used only the section of the SCID-II that
establishes whether or not a person meets diagnostic criteria for BPD. As we wanted to obtain information
about whether or not a person had simple or complex personality disorder, we also used the self-complete
IPDE screening questionnaire. This questionnaire takes less than 15 minutes to complete.69
2. We added the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) questionnaire to
the 52-week follow-up assessment to enable us to assess whether or not offering study participants
lamotrigine had any impact on their use of alcohol and illicit drugs.48
3. Initial plans to measure participants’ weight at 24 and 52 weeks were removed from the assessment
schedule because of problems identifying scales in many of the locations where follow-up assessments
were due to be conducted.
Change to design after trial commencement
An additional recruitment site was opened several months into the recruitment period (Derbyshire
Healthcare NHS Foundation Trust).
Loss to follow-up during trial participation was expected to be 15%, but an interim assessment of the
retention rate showed that it was approximately 20%. Therefore, the target sample size was increased
to 266.
METHODS
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Chapter 3 Results
Between July 2013 and October 2015, 413 participants were referred to the study, of whom 296 (71.7%)were screened. Among the potential participants who were screened, 276 (93.2%) met the inclusion
criteria and were randomised. Of the 276 participants randomised, 139 were allocated to the placebo plus
usual care arm and 137 were allocated to the lamotrigine plus usual care arm. The CONSORT flow diagram
for the LABILE trial is presented in Figure 1. Follow-up interviews took place between October 2013 and
October 2016. The rates of follow-up were similar between treatment arms; overall, 71% of participants
attended the 52-week follow-up. There were no instances in which researchers were unblinded to the
participant’s allocation status prior to completion of collection of 52-week outcome data. Scores on the
ZAN-BPD from pairs of researchers who separately rated 27 participants were highly correlated (intraclass
correlation coefficient 0.98, 95% CI 0.95 to 0.99).
Baseline characteristics of randomised participants
The demographic and clinical data of each trial arm are summarised in Table 2. The results of the outcome
assessments at baseline are presented for each arm in Table 3. In terms of baseline comparability, the
lamotrigine and placebo groups were well matched.
Referrals
(n = 413)
Screened
(n = 296)
Randomised
(n = 276)
Allocated to lamotrigine
(n = 137)
Allocated to placebo
(n = 139)
Not randomised 
(n = 20)
• Withdrew prior to
   randomisation, n = 7
• Ineligible, n = 11
• Lost contact, n = 2
Included in primary analysis
(n = 97)
Included in primary analysis
(n = 98)
Primary outcome not available 
    (n = 40)
• Withdrawn consent, n = 14
• Loss to follow-up, n = 16
• Death, n = 0
• AEs, n = 4
• Other, n = 6
Primary outcome not available 
    (n = 41)
• Withdrawn consent, n = 12
• Loss to follow-up, n = 20
• Death, n = 3
• AEs, n = 1
• Other, n = 5
FIGURE 1 The CONSORT flow diagram for the study.
DOI: 10.3310/hta22170 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 17
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Crawford et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
13
TABLE 2 Baseline demographic and clinical characteristics of study participants
Characteristic
Treatment group
Lamotrigine (N= 137) Placebo (N= 139)
Age (years) at randomisation
Mean (SD) 36.0 (11) 36.2 (11)
Sex, n (%)
Male 34 (25) 34 (24)
Female 103 (75) 105 (76)
Ethnicity, n (%)
White 123 (90) 123 (90)
Black 7 (5) 4 (3)
Asian 1 (1) 2 (1)
Mixed 6 (4) 8 (6)
Missing 0 2 (1)
Employment status, n (%)
Employed 34 (25) 26 (19)
Unemployed 95 (69) 105 (76)
Student 4 (3) 1 (1)
Retired 2 (1) 2 (1)
Missing 2 (1) 5 (4)
Total score HCL-32
Mean (SD) 21.2 (5.5) 22.5 (5.2)
n 72 75
Severity of personality disorder, n (%)
Simple 0 2 (1)
Complex 137 (100) 137 (99)
TABLE 3 Baseline outcome data from study participants
Outcome
Treatment group
Lamotrigine (N= 137) Placebo (N= 139)
ZAN-BPD
Mean score (SD) 16.6 (5.8) 17.4 (6.2)
n 135a 138a
ASSIST,b n (%)
Alcohol 53 (39) 54 (39)
Cannabis 35 (26) 27 (19)
Cocaine 11 (8) 15 (11)
Amphetamine-type stimulants 10 (7) 9 (6)
Inhalants 2 (1) 2 (1)
RESULTS
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The ZAN-BPD is a measure of symptoms and behavioural problems and the total score ranges from 0 to 36;
a lower score indicates a better outcome. The BDI measures the severity of depression symptoms and the
score ranges from 0 to 63; a lower score indicates a better outcome. The SFQ score measures social
functioning problems and the score ranges from 0 to 24; a lower score indicates a better outcome.
Adherence to protocol and trial medication
Details of the number of participants who completed each of the follow-up assessments are presented in
Table 4, broken down by study arm. The median time between randomisation and the completion of these
assessments is also presented. In total, 195 (71%) participants completed the 52-week follow-up.
Table 5 summarises the key parameters of trial medication adherence and prescribing over the course of
participation for participants in each arm. In total, 93 (34%) participants completed the trial medication per
protocol, and similar proportions were shown in both arms. Although 191 (69%) study participants were
TABLE 3 Baseline outcome data from study participants (continued )
Outcome
Treatment group
Lamotrigine (N= 137) Placebo (N= 139)
Sedatives or sleeping pills 14 (10) 16 (12)
Hallucinogens 1 (1) 4 (3)
Opiates 7 (5) 9 (6)
Other 6 (4) 2 (1)
BDI
Mean score (SD) 39.8 (11.7) 38.4 (10.2)
n 135 138
SFQ
Mean score (SD) 15.0 (4.1) 14.9 (4.5)
n 135 137
EQ-5D-3L health state
Mean score (SD) 42.6 (24) 43.8 (20.9)
n 135 137
Total number of side effects, median (IQR)
Mild 4 (2–7) 4 (1–7)
Moderate 3 (2–6) 3 (1–6)
Severe 1 (0–3) 1 (0–3)
Deliberate self-harm,c n (%)
No 39 (28) 51 (37)
Yes 96 (70) 87 (63)
Unknown 2 (2) 1 (< 0.5)
IQR, interquartile range.
a Three participants withdrew shortly after randomisation and did not complete their baseline assessments.
b Met threshold for brief intervention.
c Any act of intentional self-harm during the previous 6 months.
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TABLE 4 Adherence to follow-up visits
Time point
Treatment group
Lamotrigine (N= 137) Placebo (N= 139)
12 weeks
Number of participants who completed the assessment, n (%) 111 (81) 104 (74)
Average time in days from randomisation, mean (SD) 13.8 (2.6) 13.7 (1.9)
24 weeks
Number of participants who completed the assessment, n (%) 98 (72) 98 (71)
Average time in days from randomisation, mean (SD) 26 (3.0) 26 (2.5)
52 weeks
Number of participants who completed the assessment, n (%) 97 (71) 98 (71)
Average time in days from randomisation, mean (SD) 51.8 (3.8) 51.6 (2.4)
TABLE 5 Adherence to trial medication among 276 study participants
Outcome
Treatment group
Lamotrigine (N= 137) Placebo (N= 139)
Was the IMP received as per protocol? [n (%)]a
No 93 (68) 90 (65)
Yes 44 (32) 49 (35)
Percentage of the 52-week period that the participant was taking ≥ 100mg
Mean (SD) 60 (35) 66 (35)
Range 2–94 2–98
Number of weeks that the participant received IMP
Median (IQR) 32 (9–52) 46 (7–52)
Minimum, maximum 0, 52 0, 52
Number (%) of participants taking IMP
At 12 weeks 95 (69) 95 (68)
At 52 weeks 49 (36) 58 (42)
Dose (mg) of IMP taken
At 12 weeks
Median (IQR) 200 (200–200) 200 (200–200)
Range 25–400 25–400
At 52 weeks
Median (IQR) 200 (200–200) 200 (200–200)
Range 100–400 200–400
IMP, investigational medicinal product; IQR, interquartile range.
a Following initial titration participants stayed on a dose of ≥ 100mg throughout the remainder of the study.
RESULTS
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taking the trial medication 12 weeks after randomisation, only 107 (39%) were taking it at the end of the
1-year follow-up period. Self-rated adherence, assessed using the total score on the four-item Morisky
Medication Adherence Scale at 12, 24 and 52 weeks’ follow-up (Table 6), also showed similar levels of
compliance with trial medication.
Primary outcome
The total score on the ZAN-BPD decreased for study participants as a whole between baseline and
12 weeks and then remained fairly stable throughout the remainder of the follow-up. This pattern was
seen in both arms. No difference was seen in adjusted mean total ZAN-BPD score at 52 weeks (Table 7).
The lack of treatment effect was supported by the results of the sensitivity analyses (Table 8), which
included the following:
l using repeated measures analysis to include ZAN-BPD scores at all visits
l adjusting baseline variable with imbalance (no formal statistical testing for differences)
l multiple imputation of missing data using chained equations
l CACE analysis to investigate the impact of compliance level on treatment effect.
Secondary outcomes
Comparison of secondary outcomes at 52 weeks between those in the two treatment arms of the trial
revealed no statistically significant differences (Table 9). The proportion of people who were prescribed
psychotropic medication in the year following randomisation was 93% of those in the lamotrigine arm
and 95% of those in the placebo arm of the trial, of whom 16% in the lamotrigine arm and 17% in the
placebo arm of the trial were prescribed antipsychotic medication. We also found no evidence of clinically
important differences in secondary outcomes at 12 or 26 weeks (see Appendix 4). No differences were
seen on any of the subscores of the ZAN-BPD at 52 weeks. The adjusted mean difference for those
TABLE 6 Total score on the four-item Morisky Medication Adherence Scale at 12, 24 and 52 weeks
Time point
Treatment group
Lamotrigine (N= 137) Placebo (N= 139)
12 weeks
Median score (IQR) 3 (2–4) 3 (2–4)
n 109 99
24 weeks
Median score (IQR) 3 (2–4) 3 (2–4)
n 89 91
52 weeks
Median score (IQR) 3 (2–4) 3 (2–4)
n 88 82
IQR, interquartile range.
Note
The Morisky Medication Adherence Scale score measures the participants/adherence to trial medication. Total score ranges
from 0 to 4, with higher scores indicating better adherence.
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TABLE 8 Sensitivity analyses of primary outcome
Treatment group Adjusted difference in meansa 95% CI Analysis scenario
Lamotrigine 0.0 –1.25 to 1.26 Repeated measureb
Placebo – – –
Lamotrigine 0.0 –1.90 to 1.90 Further adjustment of baseline datac
Placebo – – –
Lamotrigine –0.1 –1.90 to 1.80 Multiple imputation of missing datad
Placebo – – –
Lamotrigine 0.3 –3.70 to 4.30 Using dichotomous treatment
adherence indicatore
Placebo – – –
Lamotrigine 0.0 0.02 to 0.03 Using continuous treatment
adherence indicatore
Placebo – – –
a Adjusted by site, baseline ZAN-BPD score, severity of personality disorder and extent of bipolarity.
b The interaction between treatment arm and visits was tested and found to be non-significant. Therefore, the final model
did not have this interaction term. Data from 234 participants were included in the model.
c Analysis was further adjusted by proportion of participants with inpatient admission at baseline.
d The multiple imputation model using chained equations includes baseline and follow-up ZAN-BPD scores, age, sex,
ethnicity, severity and extent of bipolarity.
e The definitions of dichotomous and continuous treatment adherence indicators are detailed in Data analysis.
TABLE 7 Total ZAN-BPD score at baseline and at 12, 24 and 52 weeks
Time point
Treatment group
Adjusted differencea (95% CI);
p-valueLamotrigine (N= 137) Placebo (N= 139)
Baseline
Mean score (SD) 16.6 (5.8) 17.4 (6.2) –
n 135 138
12 weeks
Mean score (SD) 11.5 (5.7) 11.5 (7.1) –
n 111 104
24 weeks
Mean score (SD) 11.9 (6.1) 11.9 (7.0) –
n 98 98
52 weeks
Mean (SD) 11.3 (6.6) 11.5 (7.7) 0.1 (–1.8 to 2.0); p= 0.91
n 97 98
a Adjusted by site, baseline ZAN-BPD score, severity of personality disorder and extent of bipolarity. Data from
195 participants were included in the primary analysis model.
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prescribed lamotrigine was –0.1 (95% CI –0.9 to 0.7) on the affective disturbance subscore, 0.1 (95% CI
–0.4 to 0.7) for cognitive disturbance, –0.1 (95% CI –0.6 to 0.5) for impulsivity and 0.0 (95% CI –0.5 to
0.5) for disturbed relationships compared with those in the placebo arm of the trial (see Appendix 4,
Table 22).
Safety
Tables 10 and 11 show that there was an excess of AEs in the placebo group but the incidence of those
classified as serious did not differ across treatment arms. There were three deaths in the trial, all of which
occurred in the placebo arm. No suspected unexpected serious adverse reactions were recorded.
Using a pro forma to enquire about the presence of specific known side effects of lamotrigine revealed no
difference between the groups at any assessment time points (Table 12).
TABLE 9 Analysis of secondary outcomes at 52 weeks
Outcome measure,
treatment group
Time point
Adjusted differencea (95% CI) p-valueBaseline 52-week follow-up
Depression score (as measured by the BDI) (N= 180), mean score (SD)
Lamotrigine 39.8 (11.7) 28.8 (16.1) –0.2 (–4.5 to 4.1) 0.937
Placebo 38.4 (10.2) 28.7 (15.5) –
Deliberate self-harmb (N = 179), n (%)
Lamotrigine 96 (70) 45 (46) 1.25 (0.68 to 2.28) 0.464
Placebo 87 (63) 38 (39) –
Social functioning (as measured by the SFQ) (N= 179), mean score (SD)
Lamotrigine 15 (4.1) 12.4 (4.3) 0 (–1.2 to 1.2) 0.987
Placebo 14.9 (4.5) 12.3 (4.9) –
Alcohol use (as measured by ASSIST) (N = 178), n (%)
Lamotrigine 53 (39) 28 (31) 1.4 (0.7 to 2.7) 0.354
Placebo 54 (39) 22 (25) –
Other substance misuse (as measured by ASSIST) (N= 178), n (%)
Lamotrigine 54 (39) 27 (30) 1.2 (0.6 to 2.3) 0.598
Placebo 47 (34) 23 (26) –
a Adjusted by site and other stratification factors. The estimate is the difference in means for continuous outcomes, and
odds ratio for binary outcomes. Severity was not included in the model for self-harm, alcohol use and any other substance
use because of collinearity.
b Any act of intentional self-harm in the 6 months prior to the baseline and 52-week interviews.
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TABLE 10 Summary of AEs by Medical Dictionary for Regulatory Activities70 codes
AE
Treatment group
Lamotrigine (N= 137) Placebo (N= 139)
Total number of AEs 246 285
Total number of participants with at least one AE, n (%) 77 (56) 93 (67)
Total number of AEs by system organ class
Blood and lymphatic system disorders 2 3
Cardiac disorders 0 1
Endocrine disorders 0 1
Eye disorders 1 6
Gastrointestinal disorders 38 55
General disorders and administration site conditions 14 14
Hepatobiliary disorders 1 0
Immune system disorders 1 1
Infections and infestations 23 38
Injury, poisoning and procedural complications 17 39
Investigations 7 3
Metabolism and nutrition disorders 2 1
Musculoskeletal and connective tissue disorders 8 7
Nervous system disorders 32 31
Pregnancy, puerperium and perinatal conditions 3 2
Psychiatric disorders 37 40
Renal and urinary disorders 1 0
Reproductive system and breast disorders 3 1
Respiratory, thoracic and mediastinal disorders 16 9
Skin and subcutaneous tissue disorders 35 31
Social circumstances 1 1
Surgical and medical procedures 4 1
Note
Adverse events data are all events reported including the SAEs.
TABLE 11 Summary of SAEs by Medical Dictionary for Regulatory Activities70 codes
SAE
Treatment group
Lamotrigine (N= 137) Placebo (N= 139)
Total number of SAEs 36 48
Total number of participants with at least one SAE, n (%) 26 (19) 32 (23)
Total number of SAEs by system organ class
Eye disorders 0 1
Gastrointestinal disorders 1 3
RESULTS
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TABLE 11 Summary of SAEs by Medical Dictionary for Regulatory Activities70 codes (continued )
SAE
Treatment group
Lamotrigine (N= 137) Placebo (N= 139)
General disorders and administration site conditions 2 1
Immune system disorders 1 0
Infections and infestations 0 1
Injury, poisoning and procedural complications 6 19
Metabolism and nutrition disorders 1 0
Musculoskeletal and connective tissue disorders 1 0
Nervous system disorders 1 0
Pregnancy, puerperium and perinatal conditions 3 2
Psychiatric disorders 16 20
Renal and urinary disorders 1 0
Respiratory, thoracic and mediastinal disorders 1 0
Social circumstances 1 0
Surgical and medical procedures 1 1
TABLE 12 Summary of side effects at baseline and at 12, 24 and 52 weeks
Time point, side effect level
Treatment group, median number of side
effects (IQR)
Lamotrigine (n= 137) Placebo (n= 139)
At baseline
Mild 4 (2–7) 4 (1–7)
Moderate 3 (2–6) 3 (1–6)
Severe 1 (0–3) 1 (0–3)
At 12 weeks
Mild 9 (5–13) 7.5 (4–14)
Moderate 6 (3–9) 6 (4–9)
Severe 2 (0–5) 1 (0–4)
At 24 weeks
Mild 11.5 (7.5–18) 13 (6–20)
Moderate 9 (5.5–12.5) 8.5 (4–14.5)
Severe 2.5 (0–7.5) 2 (0–6)
At 52 weeks
Mild 17 (11–24.5) 16 (8–25)
Moderate 12 (6–19) 11 (4.5–17)
Severe 3 (0–10) 3 (1–8.5)
IQR, interquartile range.
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Chapter 4 Economic evaluation
The availability of service-use data at each follow-up period is summarised in Table 13, which shows thatfull service-use information was available for 61% of participants in the lamotrigine group and 57% of
participants in the placebo group.
Service use
All resources used by study participants over the 52-week follow-up are summarised in Table 14. There are
some noticeable differences in the use of hospital services over the follow-up period; participants in the
lamotrigine group had an average of 12 nights of inpatient care compared with six nights of inpatient care
in the placebo group. The SDs and ranges reported alongside the means in the table suggest that this
difference in mean costs was because of a small number of participants who had long stays in hospital.
Outpatient appointments and accident and emergency attendances were similar between groups.
TABLE 13 Availability of service-use data at follow-up
Time point
Treatment group, n (%)
Lamotrigine Placebo
Baseline 135 (100) 137 (100)
12 weeks 110 (80) 104 (77)
24 weeks 98 (72) 97 (72)
52 weeks 91 (66) 88 (65)
All periods 83 (61) 77 (57)
TABLE 14 Use of services per participant over the 52-week follow-up period
Service
Treatment group
Lamotrigine (n= 83) Placebo (n= 77)
Mean (SD)a Range %b Mean (SD)a Range %b
Inpatient nights 12.66 (34.59) 0–239 46 6.37 (17.95) 0–127 35
Outpatient contacts 4.47 (7.26) 0–39 67 5.36 (9.69) 0–66 77
A&E contacts 3.86 (8.47) 0–69 70 3.52 (5.90) 0–28 61
General practice 20.43 (24.13) 0–157 98 17.16 (16.57) 1–83 100
Health care 28.90 (23.19) 0–85 95 21.23 (25.60) 0–167 95
Mental health services 12.65 (15.13) 0–84 96 13.29 (19.56) 0–148 96
Social care 13.88 (49.36) 0–429 73 12.25 (36.37) 0–291 70
Complementary services 1.02 (9.33) 0–85 1 0.08 (0.68) 0–6 1
Any medication – – 93 – – 95
Any antipsychotic medication – – 16 – – 17
A&E, accident and emergency department.
a The mean refers to the number of visits to the service.
b The percentage refers to the proportion of participants using each of these services at least once.
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In general, the use of community health services was similar in both groups. Between 98% and 100%
of participants saw their GP at least once over the period of follow-up, and, on average, the number of
times a participant saw their GP was between 17 and 20. Use of other health-care services (practice nurse,
walk-in clinic, dietitian, physiotherapist, podiatrist) and community mental health services (psychiatrist,
psychologist, care co-ordinator/key worker, psychiatric nurse, counsellor/therapist, group therapy, day
centre, drug and alcohol services, eating disorder services) was equally high.
Cost
At baseline, on average, costs were £5618 in the lamotrigine group and £3555 in the placebo group.
The adjusted difference of £2376 was not statistically significant (95% CI –£108.13 to £4860.37; p = 0.061).
The mean average cost differences between the groups are detailed in Table 15. The average drug and
prescribing cost of lamotrigine was £242.69. The difference in hospital costs between the lamotrigine and
placebo groups (£7294.09 vs. £4711.22) reflects the different average duration of inpatient stays. Other
medication costs were also higher in the lamotrigine group (£674.10 vs. £302.64), resulting in higher
average total costs in the lamotrigine group (£12,244.32) than in the placebo group (£8495.41), although
this difference in cost was not statistically significant (95% CI –£1886.61 to £3169.83; p = 0.617).
Outcomes
The EQ-5D-3L scores at baseline and all follow-up points are detailed in Table 16. There were very few
between-group differences in EQ-5D-3L scores and the resulting QALYs. The QALYs in the lamotrigine
group were 0.287 and in the placebo group were 0.299, not significantly different (95% CI –0.057 to
0.034; p = 0.612).
Cost-effectiveness analysis
The ICER for the QALY outcome using adjusted mean differences is not reported. As it was negative,
the lamotrigine treatment was dominated by the placebo. The ICER for ZAN-BPD using adjusted mean
differences was £641.61/0.22 = £2916 per unit change in ZAN-BPD score.
The uncertainty around the ICER for QALYs is shown in Figure 2. The bootstrapped replications are present
in all four quadrants of the plane: 44% appear in the less effective, more costly, quadrant; 23% in the
more costly, more effective, quadrant; 21% in the less effective, less costly, quadrant; and 12% in the less
costly, more effective, quadrant. The green line denotes the willingness-to-pay value of £20,000 per QALY.
TABLE 15 Total costs (£) per participant over the 52-week follow-up period
Cost item
Treatment group, mean cost (SD)
Differencea 95% CIa p-valueaLamotrigine (n= 83) Placebo (n= 77)
Intervention 242.69 (95.99) 0.00 (0.00) 244.78 222.71 to 266.84
Hospital 7294.09 (15,894.87) 4711.22 (10,057.64) 416.76 –1798.50 to 2632.01
Community 4033.44 (3599.40) 3481.54 (3090.88) 158.94 –437.91 to 755.79
Medication 674.10 (2457.12) 302.64 (971.04) 23.73 –302.89 to 350.35
Total 12,244.32 (17,442.80) 8495.41 (11,349.10) 641.61 –1886.61 to 3169.83 0.617
a Adjusted for by site, baseline ZAN-BPD score, severity of personality disorder (simple or complex) and score on the HCL-32
(a score of ≥ 14 or < 14).
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As there are only relatively few replications below this line, it suggests that lamotrigine treatment is not
cost-effective in terms of QALYs. The cost-effectiveness acceptability curve in Figure 3 gives a clear
representation of the cost-effectiveness plane. There are no willingness-to-pay values at which the
probability of lamotrigine treatment being cost-effective is > 35%.
The bootstrapped replications for the ZAN-BPD outcomes are shown in Figure 4. Here, the replications are
mainly to the right of the y-axis, suggesting that outcomes were slightly better in the lamotrigine treatment
group; however, the lack of a difference in cost between the groups is reflected in 54% of replications being
in the more costly, more effective, quadrant. The resulting cost-effectiveness acceptability curve in Figure 5
can only be indicative, as we do not know the willingness-to-pay values for a unit change in ZAN-BPD score.
The curve suggests that there is a probability of > 60% that lamotrigine treatment is cost-effective, but only
when willingness-to-pay values for a unit change in ZAN-BPD score are greater than £1000.
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FIGURE 2 Scatterplot on a cost-effectiveness plane of differences in costs vs. differences in QALYs.
TABLE 16 EQ-5D-3L utility scored and QALYs over the 52-week follow-up period
Time point
Treatment group
Lamotrigine Placebo
n Mean score (SD) n Mean score (SD)
Baseline 135 0.424 (0.336) 137 0.446 (0.343)
12 weeks 109 0.488 (0.365) 104 0.509 (0.344)
24 weeks 93 0.473 (0.366) 91 0.525 (0.341)
52 weeks 86 0.47 (0.355) 80 0.516 (0.353)
All-period QALYa 83 0.287 (0.023) 77 0.299 (0.292)
a Adjusted for by site, baseline ZAN-BPD score, severity of personality disorder (simple or complex) and score on the HCL-32
(a score of ≥ 14 or < 14).
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FIGURE 4 Scatterplot on a cost-effectiveness plane of differences in costs vs. differences in ZAN-BPD.
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FIGURE 3 Cost-effectiveness acceptability curve showing the probability that lamotrigine treatment is cost-effective
compared with placebo at different values that a decision-maker might be willing to pay for increases in QALYs.
0
20
40
60
80
100
Pr
o
b
ab
ili
ty
 g
ro
u
p
 A
 c
o
st
-e
ff
ec
ti
ve
0 20 40 60
Willingness to pay (£000)
FIGURE 5 Cost-effectiveness acceptability curve showing the probability that lamotrigine treatment is cost-effective
compared with placebo at different values that a decision-maker might be willing to pay for decreases in
ZAN-BPD scores.
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Sensitivity analysis
The sensitivity analyses are presented in Table 17 and show that varying the economic perspective to
include productivity losses and examining the impact of missing data through multiple imputation of
missing cases have no impact on the finding that lamotrigine treatment is not cost-saving and thus it is
unlikely to be cost-effective compared with placebo.
TABLE 17 Sensitivity analysis of differences in costs (£)
Type of analysis
Treatment group,
mean cost (SD)
Cost differencea 95% CIa p-valueaLamotrigine Placebo
Main analysis (n= 160) 12,244.32
(17,442.80)
8495.41
(11,349.10)
641.61 –1886.61 to 3169.83 0.617
Total cost including productivity
losses (n= 160)
12,378.70
(17,410.19)
8634.52
(11,299.95)
661.31 –1877.68 to 3200.30 0.608
Multiple imputation of missing
cases
12,655.64
(1822.07)
7209.06
(1283.66)
1773.42 –76.94 to 3623.77 0.06
a Adjusted by site, baseline ZAN-BPD score, severity of personality disorder (simple or complex) and score on the HCL-32
(a score of ≥ 14 or < 14).
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Chapter 5 Discussion
Data from this randomised trial of adding lamotrigine treatment to usual care for people receivingsecondary care mental health services for BPD show that the effect of this intervention was no
different from that of offering an inert placebo in addition to usual care. Follow-up data collected from
195 (70.7%) out of 276 participants at 12 months showed no difference in score on the ZAN-BPD
(adjusted mean difference 0.1, 95% CI –1.8 to 2.0). When differences in the primary outcome were
compared over the course of the 12-month follow-up period, among the 234 participants who completed
at least one follow-up assessment, no difference was observed in the adjusted ZAN-BPD score (0.0, 95% CI
–1.9 to 1.9). Although costs associated with prescribing lamotrigine were small compared with those of
inpatient and community care, we did not find evidence that offering patients with BPD lamotrigine was a
cost-effective use of resources, given the large number of resources needed to be invested for very small
changes in the ZAN-PD score outcome.
Levels of adherence to trial medication were low, with only one-third (n = 93, 33.7%) of study participants
taking trial mediation throughout the 1-year follow-up period, as specified in the study protocol. Levels of
adherence were higher during the first 12 weeks of the study, at which point two-thirds of participants
were taking trial medication (n = 190, 68.8%). However, differences between the treatment arms in the
severity of symptoms of BPD were not found at the 12-week assessment, despite medication compliance
being higher during this period. In a secondary analysis using CACE methods, we found no evidence that
greater adherence to medication was associated with any benefit to patients in the lamotrigine treatment
arm of the trial.
In addition to there being no difference in the scores on ZAN-BPD between the treatment arms, treatment
with lamotrigine was no better than placebo in terms of improvement on any other measures of mental
health. Levels of depression, likelihood of self-harming or suicidal behaviour and likelihood of problem
drug or alcohol use were all comparable across the groups at follow-up. Social functioning was also
equivalent across groups. There were no deaths in the lamotrigine arm of the trial over the 12-month
follow-up period, but three among those in the placebo arm of the trial. Quality of life, assessed using the
EQ-5D-3L, was poor in both groups, a finding which is consistent with other studies in people with BPD.47
The number of AEs reported was higher in the placebo arm than in the lamotrigine treatment arm,
and more participants in the placebo arm than in the lamotrigine treatment arm had at least one AE
(67% vs. 56%). Serious AEs were comparable across treatment arms. A pro forma to elicit information
about the known side effects of lamotrigine at each assessment showed that these were comparable
across the treatment arm. Taken together, these data suggest that lamotrigine was well tolerated in
participants in the active arm of the trial.
Strengths and weaknesses of the study
The LABILE trial is the first ever UK-based study of a medical treatment for people with BPD. Data were
collected from participants receiving secondary care from NHS mental health services in six large mental
health trusts in the north, south and centre of England. The study was designed to maximise internal validity.
This included using independent remote randomisation to avoid unmasking researchers and adhering to an
analysis plan that was finalised and shared with the Independent Data Monitoring and Ethics Committee
and Trial Steering Group prior to the start of data analysis. Members of the research team drafted their
conclusions and recommendations while still masked to treatments received by the two trial arms.
We used a validated measure of severity of BPD that is acceptable to patients and sensitive to change.37,40
All researchers were trained to use the measure, and inter-rater reliability between researchers was high.
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One of the main strengths of the LABILE trial is that participants were followed up over a 12-month period.
BPD is a long-term condition, but previous drug trials have not conducted double-blind assessments beyond
12 weeks.
We recruited 11% more participants than we originally planned and the study was sufficiently powered to
detect a minimum clinically significant difference in the severity of symptoms of BPD. We over-recruited, as
it became clear that we were not going to achieve our ambitious target of following up 85% of participants
to 12 months after randomisation. The 71% rate of follow-up that we achieved was very similar to that
achieved in a UK study of problem-solving therapy for people with personality disorder71 and may represent
a more realistic target for studies that aim to follow up people with personality disorder in community-based
studies. A planned secondary analysis using multiple imputation to account for missing data found no
difference between the study arms.
In this pragmatic trial, we attempted to replicate clinical practice in the NHS. However, one area in which
we were unable to do this was in the means by which participants obtained their medication. Most
participants typically had medication delivered to them in person or by post, rather than collecting medication
from a local pharmacy as required by this study. This meant that participants had more regular contact with
staff than they would have done in normal clinical practice (once every 2 weeks during titration and once a
month for the majority of participants once the recommended dose was achieved). Although levels of
adherence to medication were low, we believe that the additional contact that participants had with study
researchers meant that the level of adherence may have been higher in the trial than would be seen in
routine clinical practice.
Comparison with results of previous trials
In contrast to the results of the LABILE study, the two previous randomised trials of lamotrigine treatment
for people with BPD both reported positive effects.28,29 Both trials were smaller, had a larger number of
exclusion criteria and followed up participants for a shorter period of time. There are a number of other
differences between the LABILE study and these other trials, which are summarised in Table 18.
In their trial of 24 women with BPD recruited from advertisements in primary care clinics, Tritt et al.28
reported statistically significant reductions in four out of five scales of the State–Trait Anger Expression
Inventory at 8 weeks. Reich et al.29 randomised 28 men and women with BPD who were recruited from
websites and advertisements on local television and radio stations. Although a statistically significant
difference was not seen in total score on the ZAN-BPD at 12 weeks, the team reported differences in
two out of the four subscales of this measure (affective lability and impulsivity).29
The primary outcome of the LABILE study was assessed at 1 year, but in exploring the reasons for differences
in outcomes between these trials, we have focused on data from the 12-week follow-up assessment for
comparison. We believe that a number of factors may have resulted in the differences in the results between
the LABILE study and the two previous randomised trials. First, we cannot rule out the possibility that
apparent differences between groups in the two earlier trials result from chance. Randomisation does not
guarantee that treatment arms are balanced in small-scale trials and it is possible that differences in study
outcomes resulted from confounding.
The LABILE study was designed to generate evidence that can be used by secondary care mental health
services. We therefore limited our exclusion criteria and recruited people who had high levels of contact
with mental health services and major impairments in social functioning. This approach meant that we
were able to recruit people with the type of complex and severe problems that people with BPD who use
NHS secondary care mental health services generally have. A commonly used marker of severity is whether
or not people have other coexisting personality problems in addition to BPD.33 It is of note that all but one
of the people who took part in the LABILE trial met criteria for other personality disorders and had the
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types of complex personality-related problems that people in contact with NHS secondary services generally
have. In contrast, the two previous trials of lamotrigine treatment for people with BPD excluded people
who were misusing alcohol or other drugs, were actively suicidal or were receiving inpatient treatment.
Therefore, there are important differences in the sample that we recruited compared with those in the
two previous trials. For instance, 73% of participants in the trial conducted by Tritt et al.28 were employed,
compared with only 22% in the LABILE trial, and none of those recruited by Tritt et al. had a recent history
of deliberate self-harm, compared with two-thirds of participants in the LABILE trial. It is possible that
lamotrigine treatment reduces the symptoms of BPD among people who have less complex mental health
problems, higher level of social functioning and lower levels of substance misuse than those we recruited
to the LABILE trial.
Previous research has shown that people with more complex and severe personality problems are less
likely to adhere to treatment.17 It is possible that participants in the LABILE study were less adherent to trial
medication than those in the two previous trials. Tritt et al.28 did not report data on adherence. Reich et al.29
did not provide detailed information about adherence but did note that 3 (20%) out of the 15 participants
in the active arm of the trial were no longer taking medication at 12 weeks, compared with 86 (31%) of
276 participants in the LABILE trial who were no longer taking lamotrigine at 12 weeks. Although we
cannot rule out the possibility that differences in levels of adherence are responsible for differences in
TABLE 18 Comparison of the methods, design and results of the LABILE study with two previous trials of
lamotrigine for people with BPD
Characteristics of
study and sample
Trial
LABILE studya aReich et al.29 aTritt et al.28
Total sample size 276 27 24
Source of study
participants
Clinical referral from
inpatient and community
secondary care mental
health services
Members of the public who
responded to websites and
adverts on television and radio
Advertisements placed in primary
care clinics
Exclusion criteria l Psychosis
l Bipolar disorder
l Mood stabiliser
l Pregnancy
l Substance dependence
(past 60 days)a
l Actively suicidal
l Unstable medical condition
l Psychotherapy started within
past 30 days
l Abusing alcohol or drugsb
l Actively suicidal
l Somatically ill
l Any psychotropic medication
l Major depression
l Current psychotherapy
Randomisation Independent Prearranged random number
sequence
In-house
Age (years), mean 36 32 29
Female (%) 75 89 100
Employed (%) 22 Not stated 100
Mean ZAN-BPD score 17.0 18.8 Not assessed
Previous mental health
hospitalisation
34.4% in the last 6 months 51.9% lifetime 19% lifetime
Mean dose 200 mg 93.3 mg 200mg
Adherence (% taking
trial medication)
66.7 80 Not stated
Funding Public Industry No funding declared
a To facilitate comparison of data from these three studies we have used 12-week data from the LABILE study and
presented these alongside 12-week data from the trial by Reich et al.29 and 8-week data from the trial by Tritt et al.28
b In addition to exclusion criteria that were used in the LABILE study (psychosis, use of a mood stabiliser or pregnant/at risk
of pregnancy).
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outcomes between these trials, the results of the CACE analysis do not suggest that higher levels of
adherence to lamotrigine result in greater improvements in mental health.
It is possible that other aspects of the design of previous trials contributed to their positive effects.
For instance, in the LABILE trial we had a rigorous process for maintaining blinding through the use of
a computerised system, managed by an independent team that allocated study participants. In contrast,
Tritt et al.28 used an internal group to oversee treatment allocation. Insufficient information is provided in
the paper by Reich et al.29 to establish the process they used to randomise participants.
The LABILE trial is the only one of the three studies to be publicly funded. The trial by Reich et al.29 was
funded by a manufacturer of Lamictal® (a proprietary form of lamotrigine; GlaxoSmithKline UK Ltd,
Brentford, UK) and the trial by Tritt et al.28 was self-funded.
Finally, we are not aware of any unpublished trials of lamotrigine for people with BPD, but we cannot rule
out the possibility that publication bias helps to explain the absence of previous negative trials of this
treatment approach.
Implications for clinical practice
People with BPD experience high levels of emotional distress at times of crisis and may behave in an erratic
or impulsive way that puts their health at risk. Emotional distress, suicidal behaviour or thoughts of suicide
may lead people into contact with mental health services at such times. Interpersonal problems and
negative experiences of previous contact with services often make it difficult for people with BPD to trust
health-care professionals or feel reassured by their attempts to provide support and advice. In such
circumstances, the prescription of medication can provide a clear signal to the patient that they are being
taken seriously and health-care staff may also feel reassured that they are ‘doing something’ under difficult
circumstances. Data from a national audit of prescribing practice suggest that one-quarter of people who
are in contact with mental health services are being prescribed a mood stabiliser.72 Some patients report
that prescribing medication during a crisis can help bring about short-term reductions in emotional distress.
The results of the LABILE study support the clinical impression that prescribing lamotrigine can lead to
improvements in mental health but suggest that this benefit is no greater than would be found if a
placebo were to be prescribed.
Current NICE guidelines73 for the treatment of BPD recommend that future research should be conducted
to examine the impact of mood stabilisers on people with the condition, but they conclude that there was
insufficient evidence to recommend any drug treatment at the time of publication. The results of the LABILE
trial provide evidence to support current NICE recommendations and emphasise the need to use alternative
approaches to help people with BPD cope with crises and take steps to improve their mental health. The two
best-established treatments for BPD are dialectical behaviour therapy and mentalisation-based treatment.74
More recently, evidence has begun to emerge that Systems Training for Emotional Predictability and Problem
Solving (STEPPS),40 schema-focused therapy75 and day therapeutic community treatment76 can also improve
the health of people with BPD. Clinicians who are working with people in secondary care mental health
services should be aware of how they can help support people through mental health crises and how to
access evidence-based psychological treatments when these are available.
In the LABILE trial, we took great care not to recruit women who were pregnant, wanting to become
pregnant or having regular unprotected sex. Despite the assurances that potential recruits gave us, six
participants subsequently became pregnant during the course of the trial. Although lamotrigine treatment
has been shown to be relatively safe in pregnancy, this is not true of all mood stabilisers – notably sodium
valproate.23 In January 2015, the Medicines and Healthcare products Regulatory Agency issued a warning
advising clinicians to avoid prescribing sodium valproate to women of child-bearing age when possible.77
Despite this, a recent national audit showed that 11% of women with BPD who are in contact with
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secondary care mental health services are currently being prescribed this drug.72 The data from the LABILE
study showing the high level of unplanned pregnancies among women with BPD emphasise the importance
of avoiding the use of unlicensed medications, such as sodium valproate, that are potentially teratogenic.
Future research
Existing evidence-based psychological treatments for BPD are lengthy, intensive and expensive. Previous
research has demonstrated that, when compared with treatment as usual, these interventions are associated
with reduced levels of deliberate self-harm and contact with health-care services.74 However, studies that
compare the effects of these interventions with high-quality control treatments delivered in a consistent
manner show less, if any, additional benefit.78,79 Reductions in self-harm and contact with health-care
services raise the possibility that specialist psychological treatment for BPD provides an effective use of
available resources, but very few data on the costs and cost-effectiveness of these treatments exist. Further
research is needed to examine the costs and cost-effectiveness of specialist psychological treatment for
people with BPD compared with high-quality structured general psychiatric management. Such research is
needed to help policy-makers make better decisions about investing in specialist treatment services, which
many patients are currently unable to access in the NHS.
Even were such services to become more widely available, a substantial minority of people with BPD would
be unwilling or unable to use these group-based treatments. There is a pressing need for new research to
examine alternative psychological approaches to helping people with BPD cope better with emotional crises
and improve their mental health. Computer-assisted self-help interventions and training and support for
friends and family of people with BPD are all areas worthy of further exploration.80
An area of particular concern is how best to help people with severe BPD who are treated in inpatient
mental health units. Following a number of open-label studies of clozapine treatment for people with
BPD,81,82 the use of this atypical antipsychotic drug is becoming more widespread. Evidence from cohort
studies suggests that this type of medication may help reduce impulsive self-harming behaviour and reduce
the need for inpatient treatment.82 However, this drug is also associated with potential harms, including blood
dyscrasia,82 which have the potential to be fatal if not properly monitored and treated. The large number of
potential benefits and harms of clozapine for the treatment of inpatients with severe BPD provides a strong
case for a placebo-controlled randomised trial of this drug. Given the high rate of drop-out in this and other
Phase III trials of community-based interventions for people with BPD, consideration should be given using
primary outcomes that do not require direct patient contact.
Conclusions
Based on the results of this trial, we have not shown any benefits of prescribing lamotrigine for people
with BPD. These results provide further support for current NICE guidelines, which state that medication
should not be used specifically for BPD and consideration should be given to referring people for specialist
psychological treatment when these services are available.
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Appendix 1 Pro forma for recording possible side
effects of trial medication
Symptom Source Severity 
Patient 
report 
Case-notes, 
investigation 
or 
examination 
Absent 
(0) 
Mild 
(1) 
Moderate 
(2) 
Severe 
(3) 
1. Headache (b)       
2. Back pain       
3. Joint pain and swelling (d, e)       
4. Blurred vision       
5. Nystagmus (voluntary or involuntary eye 
movements) 
      
6. Conjunctivitis (pink, blood-shot white of eye)       
7. Dry mouth       
8. Palpitations (irregular heart-beat)       
9. Dizziness       
10. Unsteadiness       
11. Ataxia (coordination problems)       
12. Tremor       
13. Other movement disorders       
14. Nausea/vomiting (a, b, e)       
How often?  
Do you have an explanation for this?  
15. Loss of appetite (a, e)       
16. Loss of weight (a, c, e)       
17. Diarrhoea (a, e) 
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18. Constipation       
19. Abnormal Colour Stools (a, e)       
20.  Drowsiness (a, e)       
21. Insomnia       
22. Disorientation/confusion (b, e)       
23. Rash (a, b, c, d, e)       
Where?  
Do you have an explanation for this?  
24. Jaundice (a, e)       
25. Pruritis (a, d ,e)       
Where?  
Do you have an explanation for this?  
26. Skin lesions (d)       
Where?  
27. Blisters (d)       
Where?  
28. Mouth ulcers (d)       
29. Facial swelling (a)       
30. Lymphadenitis – swollen glands (a, c)       
31. Swollen/painful abdomen (e)       
32. Photophobia – intolerance or discomfort in 
response to light (b) 
      
  
Symptom Source Severity 
Patient 
report 
Case-notes, 
investigation 
or 
examination 
Absent 
(0) 
Mild 
(1) 
Moderate 
(2) 
Severe 
(3) 
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Symptom Source Severity 
Patient 
report 
Case-notes, 
investigation 
or 
examination 
Absent 
(0) 
Mild 
(1) 
Moderate 
(2) 
Severe 
(3) 
33. Breathlessness       
34. Fever (a, b, c, d)       
35. Aggression       
36. Agitation       
37. Suicidal thoughts 
Did you have these before taking the 
medication? 
Would you ever think of acting on these? 
      
38. Anaemia (f)       
39. Bruising (f)       
Other side effects       
 
Items labelled: Total Number 
Absent  
Mild  
Moderate   
Severe  
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Appendix 2 Modified version of the Adult Service
Use Schedule as used in this trial
Reproduced with permission from Dr Barbara Barrett (2018, King’s College London, personalcommunication).
Instructions 
 
Sections A to D should be completed in interview with the service user.  
Section E should be completed using the hospital computer database.  
 
At baseline, the schedule covers the patient’s use of services for the six months preceding the 
interview.  
At follow-up, the schedule covers the patient’s use of services since the previous interview.  
 
Use circles to select options from lists.  
 
Numbers, zeros or missing data codes should be placed in every cell. 
 
See Appendix 1 for Code List 
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Period(s) covered (tick all that apply) 
Baseline  
Baseline to 12-week  
12 to 24-week  
24 to 52-week  
If previous interviews missed, this schedule 
should cover the entire period from previous to 
current interview date. Please tick all periods that 
apply. 
DO NOT REPRODUCE WITHOUT 
PERMISSION. CONTACT 
Barbara.m.barrett@kcl.ac.uk  
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Section A: Employment  
 
A01 – What is your current occupational status? 
 
01 Full-time employment (30+ hours per week) Go to A02 
02 Part-time employment (<30 hours per week) Go to A02 
03 Employed & currently unable to work Go to A02 
04 Full-time student Go to B01 
05 Voluntary worker Go to B01 
06 Unemployed & looking for work Go to B01 
07 Unemployed & not looking for work (e.g. housewife/husband) Go to B01 
08 Unemployed & unable to work for medical reasons Go to B01 
09 Medically retired  Go to B01 
10 Retired Go to B01 
555 Not applicable Go to B01 
666
 
Research worker unable to evaluate Go to B01 
999
 
Not completed  Go to B01 
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1 Under £5,000 Go to A03 
2 £5,001-£10,000 Go to A03 
3 £10,001-£15,000 Go to A03 
4 £15,001-£20,000 Go to A03 
5 £20,001-£25,000 Go to A03 
6 £25,001-£30,000 Go to A03 
7 £30,001-£35,000 Go to A03 
8 £35,001-£40,000 Go to A03
 
9 £40,001-£45,000 Go to A03 
10 £45,001-£50,000 Go to A03 
11 £50,001+ Go to A03 
555 Not applicable Go to A03 
666
 
Research worker unable to evaluate Go to A03 
A02 – What is your approximate gross pay per year (current or most recent employment)? 
999
 
Not completed  Go to A03 
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 A03 – How many HOURS have you worked per week on average over the last six 
months/since the previous interview? 
 
 HOURS  Go to 
A04 
555 Not applicable Go to B01 
666 Research worker unable to evaluate Go to B01 
999 Not completed  Go to B01 
 
 
A04 – How many DAYS have you been absent from work due to illness over the last six 
months/since the previous interview?  
 DAYS Go to B01 
555 Not applicable Go to B01 
666 Research worker unable to evaluate Go to B01 
999 Not completed  Go to B01 
Section B: Hospital Services (FROM PATIENT REPORT)  
 
B01 – Have you had a hospital admission during the last six months/since the previous
 interview? 
 
1 Yes Go to B02 
0 No Go to B03 
555 Not applicable Go to B03 
666 Research worker unable to evaluate Go to B03 
999
 
Not completed  Go to B03 
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Mental health 
admission (code 1) or 
other reason (code 2) 
Was the admission 
planned (code 1) or 
unplanned (code 2)? 
Brief details if other 
reason (coded 2) 
Number of nights 
    
    
    
    
    
    
    
    
 
B03 – Have you been to hospital for an outpatient/day patient appointment during the last six 
months/since the previous interview? 
 
1 Yes Go to B04 
0 No Go to B05 
555 Not applicable Go to B05 
666
 
Research worker unable to evaluate Go to B05 
999
 
Not completed  Go to B05 
B02 – If yes, record details below.
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B04 – If yes, record details below. 
 
Speciality 
 (use code if possible) 
Details if speciality 
code=’other’ 
Number of appointments 
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1 Yes Go to B06 
0 No Go to C01 
555
 
Not applicable Go to C01 
666 Research worker unable to evaluate Go to C01 
999 Not completed  Go to C01 
 
B06 - If yes, record details below.  
 
Detail reason Admitted Ambulance Number of contacts
 Yes / No Yes / No  
 Yes / No Yes / No  
 Yes / No Yes / No  
 Yes / No Yes / No  
 Yes / No Yes / No  
 Yes / No Yes / No  
 Yes / No Yes / No  
 Yes / No Yes / No  
 Yes / No Yes / No  
B05 – Have you attended an accident and emergency (A&E) department in the last six 
months/since the previous interview? 
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Number of contacts  
Average duration 
(minutes) 
01 General practitioner – home   
02 General practitioner – practice   
03 General practitioner – telephone   
04 Practice nurse (in GP surgery)   
05 Care Co-ordinator   
06 Psychiatrist   
07 Psychologist   
08 Community Psychiatric nurse   
09 Occupational therapist   
10 Social worker   
11 District nurse   
12 Home help/support working   
13 Counsellor/therapist   
14 NHS Walk-in clinic   
15 Advice service e.g. citizen’s advice bureau, 
housing association 
  
16 Helpline e.g. Samaritans   
17 NHS Direct (telephone)/111   
18 Self-help groups e.g. AA   
19 Complementary therapist   
20 Other – give details   
Section C: Community services
 
C01 – Which of the following community based professionals or services have you had 
contact with over the last six months/since the previous interview?  
21 Other – give details   
22 Other – give details   
23 Other – give details   
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Name of 
Medication 
Date 
Started 
Dose 
Units 
(see codes 
below) 
 
Frequency 
(see codes 
below) 
Date 
Stopped 
Continuing
 at interview? 
e.g. Citalopram 01/04/2007 30 1 1 555 - NA Yes 
      Yes / No 
      Yes / No 
      Yes / No 
      Yes / No 
      Yes / No 
      Yes / No 
      Yes / No 
      Yes / No 
      Yes / No 
      Yes / No 
      Yes / No 
      Yes / No 
      Yes / No 
Section D: Medication 
D01 – Have you been prescribed any medication in the last six months/since the previous
interview?  
Please record psychotropic medication only. For current medication ask for current dose; for 
medication no longer taken ask for final dose.  
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Section E: DATA COLLECTION FROM HOSPITAL DATABASES 
E01 – Did the patient have a hospital admission during the last six months/since the previous 
interview? 
1 Yes Go to E02 
0 No End questionnaire. 
 
555
 
Not applicable End questionnaire. 
 
666 Research worker unable to evaluate End questionnaire. 
 
999
 
Not completed  End questionnaire. 
 
E02 – If yes, record details below.
 
Admission code 
(see below) 
Reason (if coded 
other) 
Date of admission Date of discharge 
    
    
    
    
    
    
    
 
1 Intensive care 3 Rehabilitation 
2 Acute care 4 Other - specify 
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APPENDIX 1: MODIFIED ADULT SERVICE USER SCHEDULE CODE LIST 
Code missing data as follows: 
555 Not applicable 
666 Research worker unable to evaluate 
999 Not completed  
 
1 Mental Health 22 Medical Oncology 
2 Allergy 23 Nephrology 
3 Audiology 24 Neurology 
4 Blood Test 25 Obstetrics 
5 Cardiology 26 Occupational Therapy 
6 Dental  Specialties 27 Ophthalmology 
7 Dermatology 28 Orthoptics 
8 Diabetic Medicine 29 Pain Management 
9 Diagnostic Imaging 30 Palliative Medicine 
10 Dietetics 31 Physiotherapy  
11 Endocrinology 32 Podiatry 
12 ENT 33 Rehabilitation 
13 Gastroenterology 34 Respiratory Medicine 
14 General Medicine 35 Rheumatology 
15 General Surgery
 
36 
Sexual and Reproductive Health Clinic 
(previously referred to as Family Planning 
Clinic) 
16 Genito-Urinary Medicine 37 Speech  &  Language Therapy  
17 Geriatric Medicine 38 Trauma & Orthopaedics 
18 Gynaecology 39 Tropical Medicine 
19 Hepatology 40 Urology 
20 HIV/ AIDS 41 X-Ray 
21 Infectious Diseases 42 Other 
Speciality codes for B04 
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Medication units for Section D01 
1 Milligrams (mg) 5 Depot 
2 Microgram (mcg) 6 Patch  
3 Grams (g) 7 Other – give details 
4 Millilitres (ml)   
 
Medication frequency for Section D01 
1 Once daily 7 As needed, about three times a week 
2 Twice daily 8 As needed, about twice a week 
3 Three times daily 9 As needed, about once a week 
4 Four times daily 10 As needed, about once a fortnight 
5 Once weekly 11 As needed, about once a month 
6 Once per fortnight 12 Other – give details 
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Appendix 3 Unit costs and sources for
economic evaluation
Cost item Unit cost (£) Source
Inpatient stay, per night 538–587 NHS Reference Costs 201583
Outpatient, per appointment 42–298 NHS Reference Costs 201583
Accident and emergency, per attendance 114–192 NHS Reference Costs 201583
Ambulance, per call 96 NHS Reference Costs 201583
GP contact, per minute of contact 2.82–3.60 Curtis and Burns60
Practice nurse, per minute of contact 0.72 Curtis and Burns60
Community mental health services, per minute of contact 0.68–4.35 Curtis and Burns60
Community health services, per minute of contact 0.50–2.53 Curtis and Burns60
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Appendix 4 Secondary outcomes at secondary
time points
TABLE 19 Beck Depression Inventory score at baseline and at 12, 24 and 52 weeks’ follow-up
Time point
Treatment group
Lamotrigine (N= 137) Placebo (N= 139)
Baseline
Mean score (SD) 39.8 (11.7) 38.4 (10.2)
Median score (IQR) 41 (31–49) 39 (30–46)
n 135 138
12 weeks
Mean score (SD) 29.9 (15.7) 29 (14.5)
Median score (IQR) 30 (19–42) 31 (17–40)
n 110 104
24 weeks
Mean score (SD) 30.7 (15.1) 29.9 (15.1)
Median score (IQR) 32 (20–42) 31 (17–42)
n 98 97
52 weeks
Mean score (SD) 28.8 (16.1) 28.7 (15.5)
Median score (IQR) 29 (14–42) 29 (16–41)
n 92 88
IQR, interquartile range.
TABLE 20 Deliberate self-harm at baseline and at 12, 24 and 52 weeks’ follow-up
Time point
Treatment group, n (%)
Lamotrigine (N= 137) Placebo (N= 139)
Baseline
No 39 (28) 51 (37)
Yes 96 (70) 87 (63)
Unknown 2 (2) 1 (< 0.5)
12 weeks
No 59 (54) 62 (60)
Yes 51 (46) 41 (40)
Unknown 1 (< 0.5) 1 (< 0.5)
continued
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TABLE 21 Social Functioning Questionnaire at baseline and at 12, 24 and 52 weeks’ follow-up
Time point
Treatment group
Lamotrigine (N= 137) Placebo (N= 139)
Baseline
Mean score (SD) 15 (4.1) 14.9 (4.5)
Median score (IQR) 15 (12–18) 15 (12–18)
n 135 137
12 weeks
Mean score (SD) 12.6 (4.5) 12.6 (5.2)
Median score (IQR) 12 (9–16) 12 (9–17)
n 110 104
24 weeks
Mean score (SD) 11.8 (4.3) 12.2 (4.9)
Median score (IQR) 12 (9–14) 12 (9–15)
n 98 97
52 weeks
Mean score (SD) 12.4 (4.3) 12.3 (4.9)
Median score (IQR) 13 (10–15) 12 (8–15)
n 91 88
IQR, interquartile range.
TABLE 20 Deliberate self-harm at baseline and at 12, 24 and 52 weeks’ follow-up (continued )
Time point
Treatment group, n (%)
Lamotrigine (N= 137) Placebo (N= 139)
24 weeks
No 56 (57) 60 (62)
Yes 42 (43) 37 (38)
Unknown 0 1 (< 0.5)
52 weeks
No 46 (47) 50 (51)
Yes 45 (46) 38 (39)
Unknown 6 (7) 10 (10)
Note
Denominators are the total number of participants who completed the individual follow-up.
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TABLE 22 Total score on ZAN-BPD subscores at baseline and at 52 weeks’ follow-up
Subscore
Time point
Adjusted difference in means (95% CI)a p-valueBaseline 52 weeks’ follow-up
Affective disturbance
Lamotrigine 6.9 (2.2) 4.7 (2.8) –0.1 (–0.9 to 0.7) 0.850
Placebo 7.2 (2.4) 4.9 (3.1) –
Cognitive disturbance
Lamotrigine 4 (2) 2.7 (2.2) 0.1 (–0.4 to 0.7) 0.615
Placebo 4.3 (2) 2.6 (2.1) –
Impulsivity
Lamotrigine 3 (2.1) 2.1 (2) –0.1 (–0.6 to 0.5) 0.824
Placebo 3 (1.8) 2.1 (2.1) –
Disturbed relationship
Lamotrigine 2.7 (1.9) 1.7 (1.8) 0 (–0.5 to 0.5) 0.982
Placebo 2.9 (2) 1.8 (2) –
a Adjusted by site and other stratification factors.
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